[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 536
1. Saito H, Yoshida T, Yamazaki H, Suzuki N: Conditional N-rasG12V expression promotes manifestations of neurofibromatosis in a mouse model. Oncogene; 2007 Jul 12;26(32):4714-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional N-rasG12V expression promotes manifestations of neurofibromatosis in a mouse model.
  • Human clinical neurofibromatosis type 1 (NF1) and type 2 (NF2) result from mutations and inactivation of neurofibromin and merlin genes, respectively, which negatively regulate Ras pathways.
  • To evaluate the contribution of N-Ras activity to the development of NF, we generated a novel transgenic mouse expressing oncogenic N-ras specifically in central nerve cells, neural crest-derived cells and lens epithelial cells.
  • However, plexiform neurofibroma, schwannoma, astrocytoma and pheochromocytoma were not observed in the mice, suggesting a requirement for signal(s) other than the activated N-Ras pathway to induce these tumors.
  • Thus, the activated N-Ras signal may be a main pathway for the development of the disease phenotypes characteristic of NF.
  • [MeSH-major] Disease Models, Animal. Genes, ras. Mice / genetics. Neurofibromatosis 1 / genetics. Neurofibromatosis 2 / genetics
  • [MeSH-minor] Animals. Calcium-Calmodulin-Dependent Protein Kinase Type 2. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Cataract / genetics. Cataract / pathology. Integrases / metabolism. Mice, Inbred Strains. Mice, Transgenic. Promoter Regions, Genetic

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237809.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


2. Fahey PF, Stagner BB, Martin GK: Mechanism for bandpass frequency characteristic in distortion product otoacoustic emission generation. J Acoust Soc Am; 2006 Feb;119(2):991-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is commonly observed that the levels of the 2f1-f2 and the other mf1-nf2 (m = n + 1 = integer) distortion product otoacoustic emissions (DPOAEs) initially increase in level for fixed f2 as fl -->f2, starting at f1 <f2, and then begin to decrease.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521760.001).
  • [ISSN] 0001-4966
  • [Journal-full-title] The Journal of the Acoustical Society of America
  • [ISO-abbreviation] J. Acoust. Soc. Am.
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / R01 DC000613; United States / NIDCD NIH HHS / DC / DC000613; United States / NIDCD NIH HHS / DC / DC003114
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


3. Kwaśnicka-Crawford DA, Carson AR, Scherer SW: IQCJ-SCHIP1, a novel fusion transcript encoding a calmodulin-binding IQ motif protein. Biochem Biophys Res Commun; 2006 Dec 1;350(4):890-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IQCJ-SCHIP1 is the longest isoform of a complex transcriptional unit that bridges two separate genes that encode distinct proteins, IQCJ, a novel IQ motif containing protein and SCHIP1, a schwannomin interacting protein that has been previously shown to interact with the Neurofibromatosis type 2 (NF2) protein.

  • SciCrunch. HGNC: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045569.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calmodulin-Binding Proteins; 0 / IQCJ-SCHIP1 fusion protein, human; 0 / Recombinant Fusion Proteins; 0 / Transcription Factors
  •  go-up   go-down


Advertisement
4. Rajaram V, Gutmann DH, Prasad SK, Mansur DB, Perry A: Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol; 2005 Jul;18(7):991-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common genetic alteration has been the loss of the Protein 4.1 family member, NF2, predominantly in spinal ependymomas.
  • These findings prompted us to study Protein 4.1 family members (NF2, 4.1B, 4.1R, 4.1G) in a larger cohort of 84 ependymomas (51 intracranial and 33 spinal; 11 WHO grade I, 43 grade II, 30 grade III).
  • Fluorescence in situ hybridization was performed using NF2, 4.1B, 4.1R and 4.1G probes and immunohistochemical staining was performed in a subset using merlin, Protein 4.1B and Protein 4.1R antibodies.
  • The majority of cases harbored one or more detectable genetic alterations, but we found that 4.1B gene deletions and 4.1R loss of expression were statistically more common in the pediatric vs adult, intracranial vs spinal, and grade III vs grade I/II subsets (P-values of 0.038 to <0.001).
  • Also, 4.1G deletions were seen in 11/27 (41%) patients who either died of disease or had residual/recurrent tumor vs 5/41 patients with no evidence of disease at last follow-up (P=0.009).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731777.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Cytoskeletal Proteins; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / erythrocyte membrane band 4.1 protein
  •  go-up   go-down


5. Díaz de Ståhl T, Hansson CM, de Bustos C, Mantripragada KK, Piotrowski A, Benetkiewicz M, Jarbo C, Wiklund L, Mathiesen T, Nyberg G, Collins VP, Evans DG, Ichimura K, Dumanski JP: High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. Hum Genet; 2005 Oct;118(1):35-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas may develop sporadically or in association with NF2 and schwannomatosis.
  • The fundamental aberration in schwannomas is the bi-allelic inactivation of the NF2 gene.
  • Linkage studies in schwannomatosis, a condition related to NF2, have defined a candidate 22q-locus and excluded the NF2 gene as the causative germline mutation.
  • Thus, analysis of aberrations in schwannomas may lead to the identification of putative gene(s) involved in the development of schwannoma/schwannomatosis.
  • In addition, three tumors displayed terminal deletions and four harbored overlapping interstitial deletions of various sizes encompassing the NF2 gene.
  • [MeSH-minor] Female. Genes, Neurofibromatosis 2. Humans. Male

  • Genetic Alliance. consumer health - Chromosome 22.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603 [9892679.001]
  • [Cites] Nature. 1986 Aug 14-20;322(6080):644-7 [3092103.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Nov;54(6):776-82 [7595650.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1293-302 [9399891.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):74-82 [11818139.001]
  • [Cites] Science. 2004 Jul 23;305(5683):525-8 [15273396.001]
  • [Cites] Environ Mol Mutagen. 2001;37(3):215-25 [11317339.001]
  • [Cites] Genome Res. 2003 Dec;13(12):2519-32 [14656960.001]
  • [Cites] Trends Genet. 2004 Feb;20(2):87-94 [14746990.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Oct;5(3):201-5 [1384671.001]
  • [Cites] Cell. 2004 Jun 25;117(7):953-64 [15210115.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] Am J Med Genet. 1980;7(4):507-21 [7211960.001]
  • [Cites] Hum Genet. 1999 May;104(5):418-24 [10394935.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Sep;6(9):733-43 [9298582.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):184-90 [10338003.001]
  • [Cites] Neurology. 1996 Apr;46(4):1072-9 [8780094.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):83-100 [11731936.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):45-55 [8889506.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48 [11751440.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3221-9 [12444106.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Neurology. 2003 Jun 24;60(12):1968-74 [12821741.001]
  • (PMID = 16078050.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  •  go-up   go-down


6. Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang LS: Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol; 2008 Jan;29(1):58-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.
  • HYPOTHESIS: The neurofibromatosis 2 gene, which encodes the tumor suppressor protein merlin, is frequently mutated in vestibular schwannomas (VS).
  • BACKGROUND: Despite advances in diagnosis and treatment, VS continue to cause patient morbidity.
  • METHODS: Complementary deoxyribonucleic acid microarrays were performed using cultured Schwann cells, 4 VS specimens, and 2 paired normal vestibular nerves.
  • RESULTS: Microarray analysis demonstrated that total AKT gene expression was upregulated in VS, compared with normal vestibular nerves.
  • Western blots comparing VS specimens with normal vestibular nerves showed that the AKT pathway was activated in VS but not in normal nerve.
  • [MeSH-major] Neuroma, Acoustic / genetics. Oncogene Protein v-akt / genetics. Peripheral Nervous System Neoplasms / genetics. Phosphatidylinositol 3-Kinases / genetics. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199958.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tubulin; 1F7A44V6OU / Colforsin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Oncogene Protein v-akt
  •  go-up   go-down


7. Sadler KC, Amsterdam A, Soroka C, Boyer J, Hopkins N: A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development; 2005 Aug;132(15):3561-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease.
  • A second mutant, resulting from disruption of the tumor suppressor gene nf2, develops extrahepatic choledochal cysts in the common bile duct, suggesting that this gene regulates division of biliary cells during development and that nf2 may play a role in the hyperplastic tendencies observed in biliary cells in individuals with choledochal cysts.
  • The third mutant is in the novel gene foie gras, which develops large, lipid-filled hepatocytes, resembling those in individuals with fatty liver disease.
  • These mutants illustrate the utility of zebrafish as a model for studying liver development and disease, and provide valuable tools for investigating the molecular pathogenesis of congenital biliary disorders and fatty liver disease.

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • The Lens. Cited by Patents in .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000385.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / F32 HD042920; United States / NICHD NIH HHS / HD / 1R32HD042920-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neurofibromin 2; 0 / Zebrafish Proteins; 0 / foie gras protein, zebrafish; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / Vps18 protein, zebrafish
  •  go-up   go-down


8. Cordeiro NJ, Gardner KR, Huson SM, Stewart H, Elston JS, Howard EL, Tullus KO, Pike MG: Renal vascular disease in neurofibromatosis type 2: association or coincidence? Dev Med Child Neurol; 2006 Jan;48(1):58-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal vascular disease in neurofibromatosis type 2: association or coincidence?
  • Neurofibromatosis type 2 (NF2) remains a challenging diagnosis in childhood where there may be no neurological involvement.
  • A 12-month-old male in whom NF2 was suspected because of characteristic ophthalmological and cutaneous lesions is reported.
  • A pathogenic mutation was identified on NF2 gene analysis.
  • The child developed hypertension due to renal vascular disease.
  • Although renal vascular disease is a recognized complication of neurofibromatosis type 1 (NF1), it has not been reported in NF2.
  • [MeSH-major] Hypertension, Renovascular / complications. Neurofibromatosis 2 / complications
  • [MeSH-minor] Blood Pressure. Genes, Neurofibromatosis 2. Humans. Infant. Male. Mutation

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359595.001).
  • [ISSN] 0012-1622
  • [Journal-full-title] Developmental medicine and child neurology
  • [ISO-abbreviation] Dev Med Child Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Neary WJ, Hillier VF, Flute T, Stephens D, Ramsden RT, Evans DG: Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2. J Laryngol Otol; 2010 Jul;124(7):720-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2.
  • OBJECTIVES: To identify the greatest difficulties reported by people affected by neurofibromatosis type 2, and to determine the relationship between the primary and secondary effects of the disease.
  • PARTICIPANTS: Eighty-seven adult patients under the care of the Manchester multidisciplinary neurofibromatosis type 2 team were invited to take part.
  • CONCLUSIONS: The use of a closed set neurofibromatosis type 2 questionnaire identified hearing problems and subsequent communication difficulties as the main problems faced by people with this condition.
  • [MeSH-major] Hearing Disorders / psychology. Muscle Weakness / etiology. Neurofibromatosis 2 / complications. Surveys and Questionnaires


10. Perry A, Kurtkaya-Yapicier O, Scheithauer BW, Robinson S, Prayson RA, Kleinschmidt-DeMasters BK, Stemmer-Rachamimov AO, Gutmann DH: Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature. Brain Pathol; 2005 Jan;15(1):55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the current study, we examined 24 cases (14 pure MA, 10 MA-M) using immunohistochemistry for merlin, protein 4.1 B, progesterone receptor (PR), and MIB-1, as well as FISH for NF2 and 4.1B gene dosages.
  • Nine cases of MA-M (90%) had gene deletions (NF2/4.7B), protein losses (merlin/protein 4.1B), and/or PR positivity, with a similar or identical phenotype in both components.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Gene Deletion. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Male. Membrane Proteins / metabolism. Middle Aged. Neurofibromin 2 / metabolism. Prognosis. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779237.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Neurofibromin 2; 0 / Receptors, Progesterone; 0 / protein 4.1B, human
  •  go-up   go-down


11. Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG: The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol; 2010 Aug;35(4):291-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36.
  • OBJECTIVES: To investigate the relationship between those issues concerning quality of life in patients with neurofibromatosis type 2 (NF2) as identified by the closed set NF2 questionnaire and the eight norm-based measures and the physical component summary (PCS) and mental component summary (MCS) scores of the Short Form-36 (SF-36) Questionnaire.
  • PARTICIPANTS: Eighty-seven adult subjects under the care of the Manchester Multidisciplinary NF2 Clinic were invited to participate.
  • MAIN OUTCOME MEASURES: Sixty-two (71%) completed sets of closed set NF2 questionnaires and SF-36 questionnaires were returned.
  • RESULTS: Subjects with NF2 scored less than the norm of 50 on both the physical component summary and mental component summary scores and the eight individual norm-based measures of the Short Form-36 questionnaire.
  • CONCLUSIONS: The Short Form-36 questionnaire has allowed us to relate patients' perceptions of their difficulties, as identified by the closed set NF2 questionnaire, to the physical and mental domains measured by this validated and widely used scale, and has provided further insight into areas of functioning affected by NF2.
  • [MeSH-major] Mental Health. Neurofibromatosis 2 / psychology. Perception / physiology. Quality of Life / psychology. Surveys and Questionnaires / standards

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20738338.001).
  • [ISSN] 1749-4486
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG 2nd: Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol; 2010 Sep;31(7):1135-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
  • OBJECTIVE: In vitro treatment of Nf2-deficient cells with epidermal growth factor receptor (EGFR) inhibitors can reduce cellular proliferation.
  • We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2).
  • PATIENTS: Eleven NF2 patients with progressive VS who were poor candidates for standard therapy.
  • Three patients with stable disease experienced maximum tumor shrinkage of 4%, 13%, and 14%.
  • CONCLUSION: Erlotinib treatment was not associated with radiographic or hearing responses in NF2 patients with progressive vs. Because a subset of patients experienced prolonged stable disease, time-to-progression may be more appropriate than radiographic or hearing response for anti-EGFR agents in NF2-associated vs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neurofibromatosis 2 / drug therapy. Neuroma, Acoustic / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Audiometry, Pure-Tone. Disease Progression. Erlotinib Hydrochloride. Female. Hearing Loss, Sensorineural / complications. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Speech Perception / physiology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2001 Aug;49(2):274-80; discussion 280-3 [11504103.001]
  • [Cites] Cancer Res. 2010 May 1;70(9):3483-93 [20406973.001]
  • [Cites] Otol Neurotol. 2004 Sep;25(5):791-6 [15354013.001]
  • [Cites] J Speech Hear Res. 1978 Sep;21(3):507-18 [713519.001]
  • [Cites] Ann Intern Med. 1990 Jul 1;113(1):39-52 [2112353.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):847-52 [1479599.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Sep;113(3):176-8 [7675474.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Sep;113(3):179-80 [7675475.001]
  • [Cites] Laryngoscope. 1996 Apr;106(4):457-62 [8614221.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):696-705; discussion 705-6 [9092842.001]
  • [Cites] J Speech Hear Disord. 1952 Sep;17(3):321-37 [13053556.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):75-81 [16111574.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6414-21 [16166415.001]
  • [Cites] Otol Neurotol. 2006 Jan;27(1):110-6 [16371857.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Feb;65(2):162-75 [16462207.001]
  • [Cites] Nature. 2007 Jan 25;445(7126):437-41 [17206155.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Ann Diagn Pathol. 2007 Oct;11(5):326-9 [17870017.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):50-7 [18199957.001]
  • [Cites] Mol Cell Biol. 2008 Feb;28(4):1274-84 [18086884.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2582-4 [18487575.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Aug;62(3):387-92 [17932674.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3460-2 [18612164.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Aug;5(8):487-91 [18560388.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):579-84 [19075262.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):854-65 [19029950.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] J Neurooncol. 2009 May;93(1):61-77 [19430883.001]
  • [Cites] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5032-9 [19671848.001]
  • [Cites] J Thorac Oncol. 2009 Nov;4(11):1415-9 [19692934.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):211-7 [19562255.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • (PMID = 20736812.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS024279; United States / NINDS NIH HHS / NS / P01 NS024279-23; United States / NIDCD NIH HHS / DC / R01 DC009837
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ NIHMS570073; NLM/ PMC4030413
  •  go-up   go-down


13. Chang LS, Welling DB: Molecular biology of vestibular schwannomas. Methods Mol Biol; 2009;493:163-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of vestibular schwannomas.
  • Recent advances in molecular biology have led to a better understanding of the etiology of vestibular schwannomas.
  • The underlying purpose of vestibular schwannoma research is the development of new treatment options; however, such options have not yet been established.
  • A fundamental understanding of the underlying molecular events leading to tumor formation began when mutations in the neurofibromatosis type 2 (NF2) tumor suppressor gene were identified in vestibular schwannomas.
  • The clinical characteristics of vestibular schwannomas and neurofibromatosis type 2 (NF2) syndromes have both been related to alterations in the NF2 gene.
  • Genetic screening for NF2 is now available.
  • When utilized with clinical screening, such as magnetic resonance imaging (MRI), conventional audiometry, and auditory brainstem response (ABR), the early detection of NF2 can be made, which consequently makes a significant difference in the ability to successfully treat vestibular schwannomas.
  • Additionally, the signaling pathways affected by merlin, the product of the NF2 gene, are becoming better understood.
  • Nf2-transgenic and knockout mice as well as vestibular schwannoma xenograft models are now ready for novel therapeutic testing.
  • [MeSH-major] Mutation. Neurofibromin 2 / genetics. Neuroma, Acoustic / genetics
  • [MeSH-minor] Animals. DNA Mutational Analysis. Genetic Predisposition to Disease. Humans. Magnetic Resonance Imaging. Mice. Mice, Knockout. Mice, SCID. Mice, Transgenic. Neurofibromatosis 2 / genetics. Neurofibromatosis 2 / pathology

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839347.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2
  •  go-up   go-down


14. Safavi-Abbasi S, Bambakidis NC, Zabramski JM, Workman R, Verma K, Senoglu M, Porter RW, Spetzler RF: Nonvestibular schwannomas: an evaluation of functional outcome after radiosurgical and microsurgical management. Acta Neurochir (Wien); 2010 Jan;152(1):35-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients diagnosed with neurofibromatosis type 2 were excluded.
  • In these two groups, the mean tumor volume was significantly higher in those who received combined therapy (8.59 +/- 2.29 cc), compared with radiosurgery (4.94 +/- 3.02 cc; p = 0.05) or microsurgery alone (5.38 +/- 3.23; p = 0.027).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499174.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


15. Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR: The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol; 2008 Sep;29(6):846-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.
  • OBJECTIVE: To analyze the ability of ErbB inhibitors to reduce the growth of vestibular schwannoma (VS) xenografts.
  • METHODS: Vestibular schwannoma xenografts were established in the interscapular fat pad in nude mice for 4 weeks.
  • CONCLUSION: In this preliminary study, the ErbB inhibitors trastuzumab and erlotinib decreased growth of VS xenografts in nude mice, raising the possibility of using ErbB inhibitors in the management of patients with schwannomas, particularly those with neurofibromatosis Type 2.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Otol Neurotol. 2004 Mar;25(2):155-9 [15021776.001]
  • [Cites] Arch Neurol. 1994 Feb;51(2):201-7 [8304846.001]
  • [Cites] Acta Otolaryngol. 1994 Jul;114(4):399-405 [7526595.001]
  • [Cites] Hum Genet. 1996 Aug;98(2):203-6 [8698343.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1649-54 [9403715.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6 [15142631.001]
  • [Cites] Otol Neurotol. 2004 Sep;25(5):811-7 [15354016.001]
  • [Cites] Neurosurgery. 1990 Apr;26(4):598-605 [2330081.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):101-12 [1432035.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] Hum Mol Genet. 1998 Dec;7(13):2095-101 [9817927.001]
  • [Cites] J Neurosurg. 1999 Apr;90(4):617-23 [10193604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5 [15598747.001]
  • [Cites] Laryngoscope. 2005 Mar;115(3):450-4 [15744156.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Aug;38(4):653-70 [16005724.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5589-605 [15897877.001]
  • [Cites] Breast Cancer Res Treat. 2005 Aug;92(3):251-63 [16155796.001]
  • [Cites] Mol Cells. 2005 Oct 31;20(2):196-200 [16267393.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 24;340(4):1151-7 [16405865.001]
  • [Cites] Otol Neurotol. 2006 Feb;27(2):197-208 [16436990.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Feb;65(2):162-75 [16462207.001]
  • [Cites] Glia. 2006 Apr 15;53(6):593-600 [16432850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4463-8 [16537381.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):289-94 [16155191.001]
  • [Cites] Otol Neurotol. 2006 Apr;27(3):380-92 [16639278.001]
  • [Cites] Otol Neurotol. 2006 Aug;27(5):705-12 [16868519.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4925-32 [16914581.001]
  • [Cites] Laryngoscope. 2006 Nov;116(11):2018-26 [17075413.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3505-12 [17094474.001]
  • [Cites] J Neurol. 2006 Dec;253(12):1533-41 [17219030.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] Mol Ther. 2007 Feb;15(2):279-86 [17235305.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1228-38 [17283159.001]
  • [Cites] Otol Neurotol. 2007 Aug;28(5):708-14 [17667776.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):453-7 [17667926.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):341-6 [17823551.001]
  • [Cites] J Clin Neurosci. 2007 Dec;14(12):1199-206 [17964790.001]
  • [Cites] Laryngoscope. 2008 Jan;118(1):87-93 [18090258.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):50-7 [18199957.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):79-85 [18199961.001]
  • [Cites] Glia. 2000 Jan 15;29(2):104-11 [10625327.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Hum Mol Genet. 2001 Feb 1;10(3):271-82 [11159946.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):279-90 [12082543.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):354-62 [12118253.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Curr Opin Neurol. 2003 Feb;16(1):27-33 [12544854.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 7;302(2):238-45 [12604337.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1211-21 [12761036.001]
  • [Cites] Glia. 2003 Aug;43(2):104-18 [12838503.001]
  • [Cites] J Neurosci. 2003 Aug 13;23(19):7269-80 [12917360.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):480-3 [12959433.001]
  • [Cites] Int J Oncol. 2003 Dec;23(6):1493-500 [14612918.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):20-6 [15000491.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • (PMID = 18636037.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC006211; United States / NIDCD NIH HHS / DC / K08 DC006211-01A1; United States / NIDCD NIH HHS / DC / KO8 DC006211
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ NIHMS85822; NLM/ PMC2652856
  •  go-up   go-down


16. Toh EH, Luxford WM: Cochlear and brainstem implantation. 2002. Neurosurg Clin N Am; 2008 Apr;19(2):317-29, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brainstem implant technology is currently approved for use in patients with type 2 Neurofibromatosis, who have lost integrity of auditory nerves following vestibular schwannoma removal.

  • MedlinePlus Health Information. consumer health - Cochlear Implants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18534342.001).
  • [ISSN] 1558-1349
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Biography; Classical Article; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Toh EH; Luxford WM
  •  go-up   go-down


17. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO: Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res; 2008 Jul 1;68(13):5236-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
  • Schwannomas are tumors of the nervous system that occur sporadically and in patients with the cancer predisposition syndrome neurofibromatosis type 2 (NF2).
  • Schwannomas and all NF2-related tumors are caused by loss of the tumor suppressor merlin.
  • Using our human in vitro model for schwannoma, we analyzed extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT signaling pathways, their upstream growth factor receptors, and their role in schwannoma cell proliferation and adhesion to find new systemic therapies for these tumors that, to date, are very difficult to treat.
  • We show here that human primary schwannoma cells show an enhanced basal Raf/mitogen-activated protein/ERK kinase/ERK1/2 pathway activity compared with healthy Schwann cells.
  • Due to a strong and prolonged activation of platelet-derived growth factor receptor beta (PDGFRbeta), which is highly overexpressed, ERK1/2 and AKT activation was further increased in schwannoma, leading to increased proliferation.
  • Due to the complexity of signals leading to schwannoma cell proliferation, potential new therapeutic agents should target several signaling pathways.
  • The PDGFR and c-Raf inhibitor sorafenib (BAY 43-9006; Bayer Pharmaceuticals), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFRbeta-mediated ERK1/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas.
  • We conclude that our schwannoma in vitro model can be used to screen for new therapeutic targets in general and that sorafenib is possible candidate for future clinical trials.
  • [MeSH-minor] Cells, Cultured. Enzyme Activation / drug effects. Focal Adhesion Kinase 1 / genetics. Focal Adhesion Kinase 1 / metabolism. Gene Expression Regulation, Neoplastic. Humans. Lymphokines / pharmacology. MAP Kinase Kinase 1 / metabolism. MAP Kinase Kinase 2 / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Models, Biological. Neurofibromatosis 2 / complications. Oncogene Protein v-akt / metabolism. Platelet-Derived Growth Factor / pharmacology. Receptor, Platelet-Derived Growth Factor beta / genetics. Receptor, Platelet-Derived Growth Factor beta / metabolism


18. Dohi O, Hatori M, Ichinohasama R, Hosaka M, Hashimoto S, Kokubun S: Diffuse large B-cell lymphoma arising in a patient with neurofibromatosis type I and in a patient with neurofibromatosis type II. Tohoku J Exp Med; 2006 Feb;208(2):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma arising in a patient with neurofibromatosis type I and in a patient with neurofibromatosis type II.
  • We experienced two unusual cases of diffuse large B-cell lymphoma (DLBCL), which occurred in a patient with neurofibromatosis type I and a patient with neurofibromatosis type II.
  • Neurofibromatosis I is characterized by café-au-lait spots and neurofibromas.
  • Neurofibromatosis II typically consists of bilateral schwannomas of the acoustic nerve.
  • Malignant lymphomas rarely coexist with neurofibromatosis I, and no coexistence with neurofibromatosis II has been reported.
  • The patient with neurofibromatosis I was a 50-year-old Japanese woman, clinically manifesting von Recklinghausen's disease since infancy, who noticed an egg-sized tumor in her shoulder.
  • The patient with neurofibromatosis II was a 39-year-old Japanese man who noticed multiple soft tissue tumors in his neck, buttock, and elbow.
  • The patient with neurofibromatosis I was alive without recurrence at 4 years after treatment, while the patient with neurofibromatosis II died of recurrence.
  • To the best of our knowledge, this is the first case of malignant lymphoma arising in a neurofibromatosis II patient.
  • As for neurofibromatosis I, there were some reports about occurrence of malignant lymphoma.
  • It is important to be aware of possibility of association of malignant tumors not only of the nervous system but also of unrelated to the nervous system when tumors appear in neurofibromatosis patients.
  • [MeSH-major] Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Neurofibromatosis 1 / complications. Neurofibromatosis 2 / complications. Skin Neoplasms / complications. Soft Tissue Neoplasms / complications

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434841.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. McCreery D, Han M, Pikov V: Neuronal activity evoked in the inferior colliculus of the cat by surface macroelectrodes and penetrating microelectrodes implanted in the cochlear nucleus. IEEE Trans Biomed Eng; 2010 Jul;57(7):1765-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The findings are consistent with those from patients with type II neurofibromatosis who received ABIs with both surface and microelectrodes.
  • [MeSH-minor] Animals. Cats. Electrodes, Implanted. Humans. Neurofibromatosis 2. Reproducibility of Results

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20483692.001).
  • [ISSN] 1558-2531
  • [Journal-full-title] IEEE transactions on bio-medical engineering
  • [ISO-abbreviation] IEEE Trans Biomed Eng
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS054121; United States / NIDCD NIH HHS / DC / N01-DC-4-0005; United States / NIDCD NIH HHS / DC / 1R01DC009643-01; United States / NIDCD NIH HHS / DC / R01 DC009643; United States / NINDS NIH HHS / NS / R01 NS057287
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


20. Jagannathan J, Oskouian RJ, Yeoh HK, Saulle D, Dumont AS: Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature. Skull Base; 2008 May;18(3):173-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic factors such as mutations in the neurofibromatosis-2 gene and in chromosomes 1, 9, and 10 play important roles in meningioma development and may be responsible for atypical tumors in some cases.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurochirurgie. 1966 May-Jun;12(3):361-71 [5962139.001]
  • [Cites] Humangenetik. 1975 Dec 23;30(4):343-8 [1218864.001]
  • [Cites] J Clin Endocrinol Metab. 1970 Aug;31(2):180-98 [4912771.001]
  • [Cites] Humangenetik. 1971;12(1):42-9 [5283371.001]
  • [Cites] Humangenetik. 1975;27(2):119-28 [1150234.001]
  • [Cites] Humangenetik. 1971;11(3):253-7 [5101664.001]
  • [Cites] Neuropathology. 2006 Dec;26(6):557-63 [17203593.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1200-7 [9824096.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3226-30 [9699646.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] J Neurosurg. 1998 May;88(5):870-3 [9576256.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):29-33 [9426052.001]
  • [Cites] Acta Neuropathol. 1997 Nov;94(5):479-85 [9386781.001]
  • [Cites] J Pathol. 1997 Aug;182(4):380-4 [9306957.001]
  • [Cites] J Neurosurg. 1997 Sep;87(3):368-73 [9285600.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):779-85 [9224744.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1016-26 [9149260.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):416-20 [9104940.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):611-6 [9053860.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:50-3 [8738495.001]
  • [Cites] Hum Genet. 1996 May;97(5):638-41 [8655145.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):717-23 [8687119.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Nov;92(1):73-8 [8956876.001]
  • [Cites] Hum Genet. 1996 May;97(5):632-7 [8655144.001]
  • [Cites] Neurosurgery. 1995 Nov;37(5):937-46; discussion 946-7 [8559343.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Sep;83(2):160-4 [7553588.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):365-73; discussion 373-4 [7731518.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):223-8 [7657383.001]
  • [Cites] Biochem Pharmacol. 1987 Jul 1;36(13):2115-23 [3606629.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Neurosurg. 1990 May;72(5):786-91 [2182793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5710-4 [2377607.001]
  • [Cites] J Neurosurg. 1990 Aug;73(2):248-53 [2366081.001]
  • [Cites] Humangenetik. 1970;9(2):172-84 [5423930.001]
  • [Cites] Eye (Lond). 2004 Sep;18(9):954-8 [15037887.001]
  • [Cites] Neuropathology. 2003 Dec;23(4):275-81 [14719542.001]
  • [Cites] J Neurosurg. 2003 Oct;99(4):787-91 [14567620.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4443-51 [14555517.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1117-26 [11342575.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):551-4 [11304690.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):111-7 [11147878.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] Hum Mol Genet. 2000 Jun 12;9(10):1495-500 [10888600.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] Neurosurgery. 2000 Apr;46(4):938-47; discussion 947-8 [10764269.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):692-702; discussion 702-3 [10719866.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):67-75 [10736068.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1171-7 [10770982.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2649-58 [10594860.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):25-32 [16773181.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1353-60 [16685436.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Neurosurgery. 1999 Mar;44(3):579-87; discussion 587-8 [10069595.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1189-93 [7532545.001]
  • [Cites] Brain Pathol. 1995 Jan;5(1):11-4 [7767486.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Apr 17;209(2):497-505 [7733917.001]
  • [Cites] Hum Genet. 1995 Mar;95(3):347-51 [7868131.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] Ophthalmologica. 1994;208(4):220-5 [7970552.001]
  • [Cites] Mol Carcinog. 1993;8(2):74-80 [8397797.001]
  • [Cites] J Neurosurg. 1993 Mar;78(3):456-62 [8433149.001]
  • [Cites] Childs Nerv Syst. 1991 Dec;7(8):432-6 [1665101.001]
  • [Cites] Semin Cancer Biol. 1992 Apr;3(2):89-96 [1378314.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1568-76 [1516008.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6202-5 [1933879.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Aust N Z J Surg. 1989 Nov;59(11):881-8 [2818349.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2139-44 [3052782.001]
  • [Cites] Cell. 1987 Jun 5;49(5):589-94 [2884037.001]
  • [Cites] J Med Genet. 1987 Sep;24(9):529-30 [3118032.001]
  • [Cites] Science. 1987 Apr 17;236(4799):317-9 [3105060.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2243-9 [2804914.001]
  • [Cites] Hereditas. 1984;101(1):103-13 [6490389.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):148-58 [12712009.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):675-82 [12296515.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):441-9 [12186474.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):304-11 [12082546.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):145-53 [11958368.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):149-58 [11859969.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):218-21 [11668501.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):176-84 [11561758.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):609-12 [11494043.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):88-91 [11520574.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Growth Horm IGF Res. 2001 Apr;11(2):84-91 [11472074.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):237-41 [10037170.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Neurosurgery. 1998 Oct;43(4):890-8; discussion 898-9 [9766317.001]
  • [Cites] Humangenetik. 1972;14(2):167-9 [4112733.001]
  • [Cites] Hereditas. 1972;71(1):163-8 [4142025.001]
  • (PMID = 18978964.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2459329
  • [Keywords] NOTNLM ; Aggressive / atypical / biology / meningioma / treatment
  •  go-up   go-down


21. Sestini R, Putignano AL, Ammannati F, Papi L: Detection of rearrangements in the NF2 gene using semi-quantitative multiplex fluorescent PCR. Genet Test; 2005;9(1):14-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of rearrangements in the NF2 gene using semi-quantitative multiplex fluorescent PCR.
  • Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder that predisposes to the development of bilateral vestibular schwannomas (sometimes associated with schwannomas at other locations), meningiomas, and ependymomas.
  • Point mutations that inactivate the NF2 tumor suppressor gene, located in 22q12, have been found in 45-85% of NF2 patients; in addition, large genomic deletions can be found.
  • To evaluate the presence of genomic NF2 rearrangements, we have developed a fluorescent semiquantitative multiplex PCR method.
  • Briefly, short fragments corresponding to the 17 exons, the promoter region, and the 3' end of the NF2 gene were co-amplified by PCR using dye primers.
  • The fluorescent multiplex PCR method was then used to analyze 21 NF2 individuals in which single-strand conformational polymorphism (SSCP) analysis and/or direct sequencing had revealed no NF2 point mutations; we were able to detect two deletions and one duplication in NF2 in 3 patients.
  • In conclusion, the method we developed could easily be applied in detecting NF2 deletions and duplications.
  • Discovering genomic duplications is invaluable because they are probably the most difficult molecular alterations to detect with conventional methods and, as a consequence, might be an underestimated cause of NF2.
  • [MeSH-major] Gene Rearrangement. Genes, Neurofibromatosis 2. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15857181.001).
  • [ISSN] 1090-6576
  • [Journal-full-title] Genetic testing
  • [ISO-abbreviation] Genet. Test.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


22. Landert M, Baumert BG, Bosch MM, Lütolf UM, Landau K: The visual impact of fractionated stereotactic conformal radiotherapy on seven eyes with optic nerve sheath meningiomas. J Neuroophthalmol; 2005 Jun;25(2):86-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with secondary ONSMs and those with neurofibromatosis type 2 were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937428.001).
  • [ISSN] 1070-8022
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Okada M, Wang Y, Jang SW, Tang X, Neri LM, Ye K: Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res; 2009 May 1;69(9):4043-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The NF2 tumor suppressor gene encodes an intracellular membrane-associated protein, called merlin, which belongs to the band 4.1 family of cytoskeleton-associated proteins that link cell surface glycoproteins to the actin cytoskeleton.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] Mol Biol Cell. 1999 Aug;10(8):2669-85 [10436021.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8447-54 [15378014.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5 [15598747.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Cardiovasc Res. 2006 Nov 1;72(2):339-48 [16934786.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1199-207 [17891137.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3233-43 [18071304.001]
  • [Cites] Curr Biol. 1999 Nov 4;9(21):1259-62 [10556088.001]
  • [Cites] Cell. 2000 Dec 8;103(6):919-30 [11136977.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):69-76 [11773000.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6906-14 [15466180.001]
  • [Cites] J Cell Biol. 1983 Jul;97(1):276-9 [6863394.001]
  • [Cites] J Cell Biol. 1990 Dec;111(6 Pt 1):2681-92 [2277080.001]
  • [Cites] J Cell Biol. 1991 Dec;115(6):1751-61 [1757472.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] FEBS Lett. 1995 Dec 4;376(3):172-6 [7498535.001]
  • [Cites] J Cell Biol. 1996 Oct;135(1):37-51 [8858161.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):403-15 [9486775.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7757-64 [9516485.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13375-8 [9593664.001]
  • [Cites] Mol Cell Biochem. 1999 Jul;197(1-2):195-201 [10485339.001]
  • (PMID = 19351837.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA117872-04; United States / NCI NIH HHS / CA / R01 CA117872; United States / NCI NIH HHS / CA / R01 CA117872-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / Liposomes; 0 / Neurofibromin 2; 0 / Phosphatidylinositols; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS167932; NLM/ PMC2810124
  •  go-up   go-down


24. Dereure O: [Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis: an evolving paradigm]. Ann Dermatol Venereol; 2008 Dec;135(12):888-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis: an evolving paradigm].
  • [Transliterated title] Caractérisation moléculaire de SMARCB1 et NF2 dans la schwannomatose familiale et sporadique : un paradigme qui évolue.
  • [MeSH-major] Chromosomal Proteins, Non-Histone. DNA-Binding Proteins. Neurilemmoma / genetics. Neurofibromatosis 2 / genetics. Transcription Factors
  • [MeSH-minor] Animals. Chromosomes, Human, Pair 22 / genetics. Disease Models, Animal. Humans. Mice. Mutation

  • Genetic Alliance. consumer health - Schwannomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084709.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


25. Bosch MM, Mironov A, Killer HE: Atypical manifestation of neurofibromatosis type 2 in a boy. Eye (Lond); 2005 Jun;19(6):705-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical manifestation of neurofibromatosis type 2 in a boy.
  • [MeSH-major] Cataract / diagnosis. Cranial Nerve Neoplasms / diagnosis. Neurilemmoma / diagnosis. Neurofibromatosis 2 / diagnosis. Trigeminal Nerve Diseases / diagnosis
  • [MeSH-minor] Child. Codon, Nonsense. Genes, Neurofibromatosis 2. Humans. Male


26. Kazakov DV, Pitha J, Sima R, Vanecek T, Shelekhova K, Mukensnabl P, Michal M: Hybrid peripheral nerve sheath tumors: Schwannoma-perineurioma and neurofibroma-perineurioma. A report of three cases in extradigital locations. Ann Diagn Pathol; 2005 Feb;9(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid peripheral nerve sheath tumors: Schwannoma-perineurioma and neurofibroma-perineurioma. A report of three cases in extradigital locations.
  • We present three cases of subcutaneous tumors with hybrid features of schwannoma-perineurioma (one case) and neurofibroma-perineurioma (two cases), which occurred in two women aged 50 and 52 years and one man aged 52.
  • None of the patients had signs of neurofibromatosis.
  • All tumors were surgically removed, and patients remained disease-free for 1 to 4 years.
  • The classification of the lesion into schwannoma-perineurioma and neurofibroma-perineurioma rested on histopathological and immunohistochemical findings.
  • All cases were studied for mutation of the NF2 gene, and in one case (neurofibroma-perineurioma) a point mutation was detected in exon 15 of the gene.
  • [MeSH-minor] Base Sequence. Biomarkers, Tumor / analysis. DNA Mutational Analysis. DNA, Neoplasm / analysis. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Molecular Sequence Data. Neurilemmoma / chemistry. Neurilemmoma / pathology. Neurilemmoma / surgery. Neurofibroma / chemistry. Neurofibroma / pathology. Neurofibroma / surgery. Point Mutation

  • Genetic Alliance. consumer health - Neurofibroma.
  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692946.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


27. Seki Y: [Restoration of hearing--comparing auditory brainstem implant to cochlear implant]. Brain Nerve; 2007 Apr;59(4):323-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CI restores hearing by stimulating the cochlear nerve in the cochlea for patients whose deafness has been caused by inner ear disease; ABI does it by stimulating the cochlear nucleus of the brainstem for those deaf due to bilateral cochlear nerve dysfunction.
  • In the world, up until now, more than 700 patients, almost all of whom are neurofibromatosis type 2, have undergone ABI and had hearing restored.

  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447518.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 30
  •  go-up   go-down


28. Coez A, Zilbovicius M, Ferrary E, Bouccara D, Mosnier I, Ambert-Dahan E, Kalamarides M, Bizaguet E, Syrota A, Samson Y, Sterkers O: Processing of voices in deafness rehabilitation by auditory brainstem implant. Neuroimage; 2009 Oct 1;47(4):1792-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Profound acquired deafness by post-meningitis ossified cochlea and by bilateral vestibular schwannoma in neurofibromatosis type 2 patients are two indications for auditory brainstem implantation (ABI).


29. Kim NR, Cho SJ, Suh YL: Allelic loss on chromosomes 1p32, 9p21, 13q14, 16q22, 17p, and 22q12 in meningiomas associated with meningioangiomatosis and pure meningioangiomatosis. J Neurooncol; 2009 Sep;94(3):425-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningioangiomatosis (MA) is a rare lesion appearing sporadically or as a part of neurofibromatosis 2.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Neuropathology. 2006 Jun;26(3):249-56 [16771183.001]
  • [Cites] Eur Neurol. 2003;49(3):184-6 [12646767.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1061-4 [7487408.001]
  • [Cites] Radiology. 1991 Jun;179(3):819-21 [2027998.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5995-8 [10606247.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Br J Neurosurg. 1999 Apr;13(2):167-73 [10616586.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Genomics. 1998 Jun 1;50(2):275-80 [9653655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Appl Environ Microbiol. 2001 May;67(5):2354-9 [11319122.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • (PMID = 19347254.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Aghi M, Kluwe L, Webster MT, Jacoby LB, Barker FG 2nd, Ojemann RG, Mautner VF, MacCollin M: Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype. J Neurosurg; 2006 Feb;104(2):201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
  • OBJECT: Although the manifestations of neurofibromatosis Type 2 (NF2) vary, the hallmark is bilateral vestibular schwannomas (VSs).
  • The authors studied the clinical course and genetic basis of unilateral VSs associated with other NF2-related tumors.
  • METHODS: Forty-four adults presenting with unilateral VSs and other NF2-related tumors were identified.
  • Molecular analysis of the NF2 locus was performed in available tumors and paired blood specimens.
  • Thirty-eight harbored other intracranial tumors and 27 had spinal tumors, with most lesions situated ipsilateral to the vs. No patient had a relative with NF2, although two of 63 offspring had isolated NF2-related findings.
  • Mosaicism for the NF2 gene mutation was proven in eight patients.
  • CONCLUSIONS: The authors describe the clinical features of this unique phenotype--unilateral VS with other NF2-related tumors.
  • Persons with this phenotype should undergo evaluation and monitoring similar to that conducted in patients with NF2, and the possibility of aggressive contralateral VS formation should be considered in their treatment.
  • [MeSH-major] Neurofibromatosis 2 / complications. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Child. DNA Mutational Analysis. Disease Progression. Female. Functional Laterality. Genes, Neurofibromatosis 2. Humans. Male. Middle Aged. Phenotype. Prognosis. Retrospective Studies


31. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q: Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene; 2007 Feb 8;26(6):836-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutation or loss of expression of merlin is responsible for neurofibromatosis type 2 (NF2), which is characterized by the development of schwannomas and other tumors of the nervous system.
  • In the present study, we show that increased expression of wild-type merlin in Tr6BC1 schwannoma cells inhibits HA binding to CD44.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORESCEIN .
  • Hazardous Substances Data Bank. D&C Yellow No. 8 .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16953231.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Amino Acids; 0 / Antigens, CD44; 0 / Cytoskeletal Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / ezrin; 9004-61-9 / Hyaluronic Acid; TPY09G7XIR / Fluorescein
  •  go-up   go-down


32. Feucht M, Griffiths B, Niemüller I, Haase W, Richard G, Mautner VF: Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders. Acta Ophthalmol; 2008 Dec;86(8):882-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders.
  • PURPOSE: Ophthalmic features of neurofibromatosis 2 (NF2) include juvenile cataract, retinal hamartomas and tumours of the cranial nerves.
  • Eleven of 73 patients had a nystagmus, mostly caused by peripheral-vestibular disturbance.
  • In the subgroup analysis of NF2 mutation types, the relative risk for cranial nerve palsies and negative stereopsis was statistically significantly increased for the nonsense mutation group.
  • CONCLUSIONS: The present study is, to our knowledge, the first to examine a larger collection of NF2 patients for strabismological and neuro-ophthalmological lesions.
  • Compared with the normal population, our sample showed a higher amount of strabismus, refractive errors and an increased incidence of vestibular nystagmus.
  • [MeSH-major] Eye Diseases / epidemiology. Eye Diseases / etiology. Nervous System Diseases / epidemiology. Nervous System Diseases / etiology. Neurofibromatosis 2 / complications. Strabismus / epidemiology. Strabismus / etiology
  • [MeSH-minor] Codon, Nonsense. Cranial Nerve Diseases / epidemiology. Cranial Nerve Diseases / etiology. Depth Perception. Genes, Neurofibromatosis 2. Humans. Incidence. Nystagmus, Pathologic / epidemiology. Nystagmus, Pathologic / etiology. Paralysis / epidemiology. Paralysis / etiology. Refractive Errors / epidemiology. Refractive Errors / etiology. Retrospective Studies. Vestibular Diseases / complications. Vestibular Diseases / etiology. Vision, Binocular. Visual Acuity

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976311.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon, Nonsense
  •  go-up   go-down


33. Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC: Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle; 2005 Dec;4(12):1862-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in Nf2, p16/Cdkn2a, p19/Arf and Trp53 genes and protein expression of p15/Cdkn2b and Cdk4 were analyzed in 12 cultures from mice hemizygous for Nf2 (asb-Nf2(KO3/+)) and 4 wild type counterparts (asb-Nf2(+/+)).
  • We have found frequent inactivations of p16/Cdkn2a, p19/Arf (or P14/ARF) and p15/Cdkn2b, coinactivation of p16/Cdkn2a and p15/Cdkn2b and low rate of Trp53 mutations in both asb-Nf2(KO3/+) and asb-Nf2(+/+) mesothelioma cells.
  • Loss of heterozygosity at the Nf2 locus was detected in 10 of 11 asb-Nf2(KO3/+) cultures and Nf2 gene rearrangement in one asb-Nf2(+/+) culture.


34. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F: Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A; 2010 Feb;152A(2):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mapping birth dates of affected individuals from families onto regional birth rates has allowed an estimate of birth incidence, disease prevalence, and de novo mutation rates.
  • Disease prevalence in order of frequency were for neurofibromatosis type 1 (NF1): 1 in 4,560; familial adenomatous polyposis (FAP): 1 in 18,976; nevoid basal cell carcinoma [Gorlin syndrome (GS)]: 1 in 30,827; neurofibromatosis type 2 (NF2) 1 in 56,161; and von Hippel Lindau (VHL) 1 in 91,111.
  • The proportions due to de novo mutation were: 42% (NF1); 16% (FAP); 26% (GS); 56% (NF2); and 21% (VHL).
  • Estimates for NF1, NF2, FAP, and VHL are in line with previous estimates, and we provide the first estimates of birth incidence and de novo mutation rate for GS.
  • [MeSH-minor] Adenomatous Polyposis Coli / genetics. Basal Cell Nevus Syndrome / genetics. DNA Mutational Analysis. Great Britain. Humans. Incidence. Mutation. Neurofibromatosis 2 / genetics. Prevalence. Syndrome. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease / genetics

  • Genetics Home Reference. consumer health - Gorlin syndrome.
  • Genetics Home Reference. consumer health - neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20082463.001).
  • [ISSN] 1552-4833
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


35. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T: The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem; 2007 Mar 16;282(11):8256-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (ii) selective miRNAs including let-7a are up-regulated and contribute to the survival effects of enforced IL-6 activity; and (iii) let-7a contributes to the constitutively increased phosphorylation of Stat-3 by a mechanism involving the neurofibromatosis 2 (NF2) gene.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220301.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK069370-02; United States / NIDDK NIH HHS / DK / R01 DK069370; United States / NIDDK NIH HHS / DK / DK069370; United States / NIDDK NIH HHS / DK / R01 DK069370-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / MicroRNAs; 0 / Neurofibromin 2; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / mirnlet7 microRNA, human
  •  go-up   go-down


36. Guntinas-Lichius O: Hearing improvement after bevacizumab for neurofibromatosis type 2. N Engl J Med; 2009 Oct 29;361(18):1809-10; author reply 1810-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hearing improvement after bevacizumab for neurofibromatosis type 2.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hearing Loss / drug therapy. Neurofibromatosis 2 / complications. Neuroma, Acoustic / drug therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • (PMID = 19864683.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


37. Girard N: [Imaging features of neurofibromatosis type 2]. J Neuroradiol; 2005 Jun;32(3):198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging features of neurofibromatosis type 2].
  • [Transliterated title] Imagerie de la neurofibromatose de type 2.
  • Neurofibromatosis type 2 (NF2) is a separate entity from von Recklinghausen's disease (NF1) and is much less frequent than NF1.
  • The major feature of NF2 is the presence in nearly all affected individuals of bilateral vestibular schwannomas.
  • Imaging of the entire central nervous system is necessary, including evaluation of the cerebral parenchyma, the pontocerebellar angles, the spinal cord as well as the lumbar nerve roots, because the affected individuals can develop tumours from schwann cells, meningeal cells and from ependymocytes.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Neurofibromatosis 2 / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16134301.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 14
  •  go-up   go-down


38. de Raedt T, Cools J, Debiec-Rychter M, Brems H, Mentens N, Sciot R, Himpens J, de Wever I, Schöffski P, Marynen P, Legius E: Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology; 2006 Dec;131(6):1907-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.
  • BACKGROUND & AIMS: Intestinal neurofibromatosis (Online Mendelian inheritance in Man database number 162220) is an alternate form of neurofibromatosis.
  • Patients present with neurofibromas limited to the intestine in the absence of any other typical features of NF1 and NF2.
  • At present, the molecular basis of intestinal neurofibromatosis remains elusive.
  • The aim of the present study was to find the gene responsible for intestinal neurofibromatosis and to characterize functionally the mutation.
  • METHODS: Three candidate genes (NF1, KIT, and PDGFRA) were screened for mutations in 3 sisters diagnosed with intestinal neurofibromatosis.
  • The clinical phenotype in the reported family resembles the syndrome of familial gastrointestinal stromal tumors (familial GIST).
  • Somatic activating mutations in KIT and PDGFRA are frequent in sporadic GISTs, and mutations in both genes have also been described in familial GISTs.
  • CONCLUSIONS: The inherited PDGFRA mutation in the reported family shows that intestinal neurofibromatosis is allelic to familial GIST caused by PDGRA mutations.
  • We therefore propose that these tumors be classified as familial KIT-negative gastrointestinal stromal tumors.
  • [MeSH-major] Gastrointestinal Stromal Tumors / classification. Gastrointestinal Stromal Tumors / genetics. Intestinal Diseases / genetics. Mutation / genetics. Neurofibromatoses / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Adult. Aged. Cells, Cultured. DNA / genetics. Female. Gene Expression Regulation. Humans. Male. Middle Aged. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / metabolism. Pedigree. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism


39. Lim JY, Kim H, Jeun SS, Kang SG, Lee KJ: Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. Biochem Biophys Res Commun; 2006 Feb 24;340(4):1151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous studies have suggested that the NF2 protein merlin is involved in the regulation of abnormal cell growth and proliferation.


40. Ferrer M, Schulze A, Gonzalez S, Ferreiro V, Ciavarelli P, Otero J, Giliberto F, Basso A, Szijan I: Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases. Neurosci Lett; 2010 Aug 9;480(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases.
  • Neurofibromatosis 2 is a familial syndrome characterized by the development of schwannomas, meningiomas and ependymomas.
  • These tumors are developed as the outcome of NF2 gene (22q12) inactivation.
  • The NF2 protein, merlin or schwannomin belongs to the Ezrin, Radixin, Moesin (ERM) family involved in the cytoskeletal network and has a tumor suppressor function.
  • Inactivating mutations occur as "de novo" (more frequently) or as inherited, and most of them are frameshift or nonsense.
  • Our aim is to study NF2 gene alterations in Argentine patients and relate them to clinical features.
  • 1) at-risk haplotype by STR-segregation analysis and 2) NF2 gene mutations by SSCP/heteroduplex/sequencing.
  • [MeSH-major] Neurofibromatosis 2 / genetics. Neurofibromin 2 / genetics


41. Otto SR, Shannon RV, Wilkinson EP, Hitselberger WE, McCreery DB, Moore JK, Brackmann DE: Audiologic outcomes with the penetrating electrode auditory brainstem implant. Otol Neurotol; 2008 Dec;29(8):1147-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The penetrating electrode auditory brainstem implant (PABI) is an extension of auditory brainstem implant (ABI) technology originally developed for individuals deafened by neurofibromatosis type 2.
  • PATIENTS AND PROTOCOL: In a prospective clinical trial, 10 individuals, all with neurofibromatosis type 2, received a PABI after vestibular schwannoma removal via a translabyrinthine approach.
  • [MeSH-major] Auditory Brain Stem Implants. Deafness / surgery. Hearing Aids. Hearing Tests. Neurofibromatosis 2 / complications. Prostheses and Implants

  • MedlinePlus Health Information. consumer health - Hearing Aids.
  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931643.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / N01-DC-1-2105; United States / NIDCD NIH HHS / DC / N01-DC-4-0005
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


42. Kazakov DV, Vanecek T, Sima R, Kutzner H, Michal M: Dendritic cell neurofibroma with pseudorosettes lacks mutations in exons 1-15 of the neurofibromatosis type 2 gene. Am J Dermatopathol; 2005 Aug;27(4):286-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell neurofibroma with pseudorosettes lacks mutations in exons 1-15 of the neurofibromatosis type 2 gene.
  • Dendritic cell neurofibroma with pseudorosettes (DCNWPR) is a recently proposed variant of neurofibroma with a distinctive microscopic appearance that is produced by a pseudorosette pattern formed by small, dark, lymphocyte-like cells (Type I cells) arranged concentrically around larger cells, with pale-staining vesicular nuclei and copious faintly eosinophilic cytoplasm (Type II cells).
  • Although DCNWPR appears not to be associated with neurofibromatosis (NF), 1 patient with DCNWPR has been described and suggested to have a form of NF because of multiple skin lesions, with 2 of them being DCNWPR as confirmed histologically.
  • The aim of this study was to find out whether the neurofibromatosis type 2 (NF2) gene is mutated in DCNWPR.
  • All patients clinically presented with a small solitary lesion that was clinically diagnosed as fibroma or neurofibroma, and none of the patients had signs of NF.
  • Exons 1 to 15 of the NF2 gene were amplified by PCR using primers previously published.
  • DCNWPR appears to have no mutation in exons 1-15 of the NF2 gene.
  • Given the relatively small number of cases studied, it seems premature to declare that a mutation of the NF2 gene is not involved in DCNWPR, as the possibility cannot be excluded that mutations were present but remained undetected because they occurred in exons that were not examined.
  • [MeSH-major] Dendritic Cells / pathology. Genes, Neurofibromatosis 2. Neurofibroma / genetics. Neurofibroma / pathology


43. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E: Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer; 2009 May;64(2):140-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional inactivation of NF2/merlin in human mesothelioma.
  • The tumor suppressor merlin is encoded by the neurofibromatosis type 2 gene (NF2) which is located on chromosome 22q12 and mutations in this gene have been found in 40% of mesothelioma.
  • Experimental animal models indicate that disruption of the NF2 signalling pathway, together with a deficiency in ink4a, is essential for mesothelioma development.
  • Our hypothesis was that in human mesothelioma without detectable NF2 mutations, regulators of NF2/merlin activity such as CPI-17 would be altered.
  • CPI-17 is an oncogene inhibiting the NF2/merlin phosphatase which is necessary to maintain NF2/merlin activity.
  • Samples obtained from 44 mesothelioma, 3 asbestosis patients and 6 normal pleura from non-asbestos related disease patients were analyzed.
  • Truncated NF2 transcripts or presence of isoform II only were observed in 11 mesothelioma samples.
  • In all other mesothelioma samples only NF2 isoform I or isoforms I and II were detected.
  • Unexpected variants in addition to wild-type were identified in 24 mesothelioma samples.
  • NF2 protein was either truncated or phosphorylated on Ser 518 in primary cultures derived from 25 tumors.
  • CPI-17 expression was significantly increased in tumor samples without deleted NF2 compared to normal pleura and tumor expressing truncated NF2.
  • Our results support the hypothesis that the disruption of NF2 signalling is essential for the development of human mesothelioma.
  • In tumors where no NF2 truncation can be detected, NF2 is rendered inactive by phosphorylation of Ser 518 and this can be explained at least in part by an increased expression of CPI-17.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Neurofibromatosis 2. Mesothelioma / metabolism. Neurofibromin 2 / metabolism. Phosphoprotein Phosphatases / metabolism


44. Sayagués JM, Tabernero MD, Maíllo A: [Cytogenetic alterations in meningioma tumors and their impact on disease outcome]. Med Clin (Barc); 2007 Feb 17;128(6):226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic alterations in meningioma tumors and their impact on disease outcome].
  • [Transliterated title] Alteraciones citogenéticas en meningiomas y su impacto en la evolución de la enfermedad.
  • Accordingly, while the presence of monosomy 22/22q-, associated with mutation of the NF2, BAM22, RRP22, GAR22, MN1, SMARCB1, CLH22 and/or LARGE genes, is associated with neoplasic transformation, other alterations such us monosomy 14, del(1p), different chromosomal abnormalities localized at 9p, 10q and 17q and complex karyotypes are frequently related to tumor progression.
  • From the clinical point of view, currently available information about the impact of the different cytogenetic abnormalities on disease behavior and patient outcome is still scanty; nevertheless, the presence of gains of chromosome 22 in the context of a hyperdiploid karyotype, as well as del(1p) and monosomy 14 have been associated with a statistically significantly shorter recurrence-free survival, this later abnormality showing an independent prognostic value.
  • [MeSH-minor] Cell Transformation, Neoplastic. Disease Progression. Humans. Prognosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17335728.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 110
  •  go-up   go-down


45. Gabeau-Lacet D, Engler D, Gupta S, Scangas GA, Betensky RA, Barker FG 2nd, Loeffler JS, Louis DN, Mohapatra G: Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. J Neuropathol Exp Neurol; 2009 Oct;68(10):1155-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighty-five percent of samples exhibited loss of 22q, including the neurofibromatosis type 2 gene.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):145-53 [11958368.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1014-20 [14749765.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):171-3 [14751635.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Aug;16(4):265-9 [8875241.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Aug;56(8):879-86 [9258258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] DNA Res. 1997 Oct 31;4(5):345-9 [9455484.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jun;103(2):95-100 [9614906.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3226-30 [9699646.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Neurol Res. 1998 Oct;20(7):612-6 [9785589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] Mol Carcinog. 1999 Apr;24(4):300-4 [10326867.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):612-20 [15632063.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2034-40 [17024118.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):43-55 [17943972.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7022-8 [18056178.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Neuro Oncol. 2009 Apr;11(2):192-200 [18923191.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1763-9 [12087464.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Adv Anat Pathol. 2000 May;7(3):153-7 [10809221.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):393-8 [11159177.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):88-91 [11520574.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):316-20 [12355089.001]
  • (PMID = 19918127.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32CA09216; United States / NCI NIH HHS / CA / R21 CA106695; United States / NCI NIH HHS / CA / R33 CA106695-03; United States / NCI NIH HHS / CA / T32 CA009216-28; United States / NCI NIH HHS / CA / CA009216-28; United States / NCI NIH HHS / CA / T32 CA009216; United States / NCI NIH HHS / CA / CA106695-03; United States / NCI NIH HHS / CA / R21 CA106695-02; United States / NCI NIH HHS / CA / R33 CA106695; United States / NCI NIH HHS / CA / CA106695-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS187123; NLM/ PMC2847373
  •  go-up   go-down


46. Dickinson PJ, Surace EI, Cambell M, Higgins RJ, Leutenegger CM, Bollen AW, LeCouteur RA, Gutmann DH: Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol; 2009 Sep;46(5):884-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
  • Several tumor suppressor genes have been implicated in meningioma pathogenesis in humans, including the neurofibromatosis 2 (NF2), protein 4.1B (4.1 B), and tumor suppressor in lung cancer-1 (TSLC1) genes.
  • We investigated the expression of these tumor suppressor genes in a series of spontaneous canine meningiomas using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) (NF2; n = 25) and western blotting (NF2/merlin, 4.1B, TSLC1; n = 30).
  • NF2 gene expression assessed by western blotting and RT-PCR varied considerably between individual tumors.
  • Complete loss of NF2 protein on western blotting was not seen, unlike 4.1B and TSLC1.
  • Incidence of TSLC1 abnormalities was similar to that seen in human meningiomas, while perturbation of NF2 and 4.1B appeared to be less common than reported for human tumors.
  • [MeSH-major] Dog Diseases / pathology. Gene Expression Regulation, Neoplastic / physiology. Meningeal Neoplasms / veterinary. Meningioma / veterinary. Neurofibromatosis 2 / metabolism. Neurofibromin 2 / metabolism. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19429976.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


47. Chadee DN, Xu D, Hung G, Andalibi A, Lim DJ, Luo Z, Gutmann DH, Kyriakis JM: Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A; 2006 Mar 21;103(12):4463-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.
  • We show that the activation of ERK and the proliferation of human schwannoma cells bearing a loss-of-function mutation in the neurofibromatosis 2 (NF2) gene require MLK3.
  • We find that merlin, the product of NF2, blunts the activation of both ERK and c-Jun N-terminal kinase (JNK).


48. Jin Y, Row KH: [Optimum separation conditions of catechin compounds by HCI program in reversed-phase high performance liquid chromatography]. Se Pu; 2006 Sep;24(5):466-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The elution profiles were calculated by the plate theory based on the linear and quadratic equations of retention factor, In k = ln kw + SF, k = A + B/F, ln k = L + MF + NF2, where F is the volume fraction of methanol in the mobile phase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165539.001).
  • [ISSN] 1000-8713
  • [Journal-full-title] Se pu = Chinese journal of chromatography
  • [ISO-abbreviation] Se Pu
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8R1V1STN48 / Catechin
  •  go-up   go-down


49. Arístegui M, Denia A: Simultaneous cochlear implantation and translabyrinthine removal of vestibular schwannoma in an only hearing ear: report of two cases (neurofibromatosis type 2 and unilateral vestibular schwannoma). Otol Neurotol; 2005 Mar;26(2):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous cochlear implantation and translabyrinthine removal of vestibular schwannoma in an only hearing ear: report of two cases (neurofibromatosis type 2 and unilateral vestibular schwannoma).
  • STUDY DESIGN: This is a retrospective case review of two cases of vestibular schwannoma (VS) in the only hearing ear in which a cochlear implant (CI) was placed simultaneous to removal of VS through a modified enlarged translabyrinthine approach.
  • PATIENTS: The study includes a report of two cases: a case of a Neurofibromatosis Type 2 (NF2) patient who received a MEDEL COMBI 40+ CI after a translabyrinthine surgery for removal of a large (4.0 cm) cystic VS; and a patient with a 1.2 cm VS in the only hearing ear who was submitted to the same strategy and operation, using a Nucleus 24 Contour CI.
  • CONCLUSION: The present cases demonstrate that cochlear implantation can be successful after a translabyrinthine approach for VS, regardless of the tumor size, the kind of patient (NF2, unilateral VS), and the type of implant.
  • [MeSH-major] Cochlear Implantation / methods. Hearing Loss, Bilateral / surgery. Neurofibromatosis 2 / surgery. Neuroma, Acoustic / surgery
  • [MeSH-minor] Audiometry, Pure-Tone. Cochlear Nerve / pathology. Cochlear Nerve / surgery. Combined Modality Therapy. Ear, Inner / surgery. Ear, Middle / pathology. Ear, Middle / surgery. Electrodes, Implanted. Facial Nerve / pathology. Facial Nerve / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Prosthesis Design. Reoperation / methods. Speech Discrimination Tests. Tomography, X-Ray Computed


50. Xiao HJ, Au DK, Yau H, Chow CK, Fan YW, Wei WI: Neurofibromatosis type 2 and auditory brainstem implantation. Chin Med J (Engl); 2007 Aug 20;120(16):1456-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 and auditory brainstem implantation.
  • [MeSH-major] Auditory Brain Stem Implantation / methods. Neurofibromatosis 2 / surgery


51. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas.
  • PURPOSE: To evaluate the effectiveness and long-term outcome of stereotactic radiosurgery (SRS) for acoustic neuromas (AN).
  • Two patients suffered from neurofibromatosis type 2.
  • [MeSH-major] Hearing / radiation effects. Neuroma, Acoustic / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Facial Nerve / radiation effects. Facial Paralysis / etiology. Female. Hearing Loss / etiology. Humans. Male. Middle Aged. Neurofibromatosis 2 / complications. Radiation Injuries / etiology. Trigeminal Neuralgia / etiology

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16464537.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Roche PH, Bouvier C, Chinot O, Figarella-Branger D: Genesis and biology of vestibular schwannomas. Prog Neurol Surg; 2008;21:24-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genesis and biology of vestibular schwannomas.
  • This review chapter is a synthesis of the recent literature about pathogenesis of schwannomas with emphasis on vestibular schwannomas (VSs).
  • The understanding of this mechanism has been gained from molecular genetic studies of neurofibromatosis type 2 (NF2) patients, in whom mutations of a tumor suppressor gene (NF2 gene) was clearly identified.
  • S/M is the normal NF2 gene product.
  • Lack of normal S/M protein in the schwannoma cell is due to gene mutation in 50% of sporadic VSs.
  • Apart from the involvement of the S/M pathway, the authors review the potential role of other genetic abnormalities and growing factors that are supposed to be involved in the pathogenesis of vs. Understanding the pathways of action and regulation of S/M may provide the basics for identifying potential therapeutic targets, which is of paramount importance for a better management of NF2 patients.
  • [MeSH-major] Genes, Neurofibromatosis 2 / physiology. Neurofibromin 2 / physiology. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology
  • [MeSH-minor] Epigenesis, Genetic / physiology. Humans. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / genetics

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810196.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neurofibromin 2
  • [Number-of-references] 43
  •  go-up   go-down


53. Hasegawa T, Fujitani S, Katsumata S, Kida Y, Yoshimoto M, Koike J: Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years. Neurosurgery; 2005 Aug;57(2):257-65; discussion 257-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years.
  • OBJECTIVE: Many investigators have reported successful treatment of vestibular schwannomas with gamma knife radiosurgery (GKRS).
  • However, long-term outcomes should be evaluated before concluding that GKRS is truly safe and effective for the treatment of vestibular schwannomas.
  • METHODS: Between May 1991 and December 1998, 346 consecutive patients (excluding those presenting with neurofibromatosis Type 2) were treated with GKRS.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Neuroma, Acoustic / surgery. Radiosurgery / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094154.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Sharma MS, Singh R, Kale SS, Agrawal D, Sharma BS, Mahapatra AK: Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2. J Neurooncol; 2010 Jun;98(2):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2.
  • To analyze the effect of Gamma Knife radiosurgery (GKS) on tumor control and hearing preservation rates in patients with vestibular schwannomas (VS) in a setting of neurofibromatosis type 2 (NF 2), a retrospective study was carried out at a tertiary-level referral Gamma Knife unit.
  • Dose plans, pre- and postoperative radiology, and follow-up clinical records of patients with NF 2 who had undergone GKS for VS using a Leksell Gamma Knife (Elekta Instruments AB, Stockholm, Sweden) model B unit from 1997 to 2008 were reviewed.
  • Twenty-four patients had bilateral vs. The commonest clinical presentation was hearing loss and tinnitus.
  • GKS for VS provides satisfactory tumor control and hearing preservation in patients with NF 2.
  • [MeSH-major] Hearing / physiology. Neurofibromatosis 2 / surgery. Radiosurgery / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ASHA. 1981 Jul;23(7):493-500 [7052898.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):195-199 [28306432.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):696-705; discussion 705-6 [9092842.001]
  • [Cites] Neurochirurgie. 2000 Sep;46(4):339-53; discussion 354 [11015671.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):383-89; discussion 389-90 [10825525.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):447-53 [17704364.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):390-8 [19109818.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Neurosurgery. 2007 Mar;60(3):460-8; discussion 468-70 [17327790.001]
  • [Cites] Neurosurgery. 2005 Aug;57(2):257-65; discussion 257-65 [16094154.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] No Shinkei Geka. 1995 Feb;23(2):131-5 [7877733.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1):77-85; discussion 77-85 [16823303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):845-51 [17379451.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1288-93 [12933938.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1450-9 [14630285.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • (PMID = 20405305.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Niv MY, Iida K, Zheng R, Horiguchi A, Shen R, Nanus DM: Rational redesign of neutral endopeptidase binding to merlin and moesin proteins. Protein Sci; 2009 May;18(5):1042-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that the ERM-related protein merlin (NF2) does not bind NEP or its cytosolic region.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Apr 28;101(3):259-70 [10847681.001]
  • [Cites] Biopolymers. 2009 Jul;91(7):505-13 [19226619.001]
  • [Cites] J Clin Neurosci. 2001 Jan;8(1):4-7 [11148074.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1425-36 [11163215.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] J Cell Sci. 2002 Nov 1;115(Pt 21):3991-4000 [12356905.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):502-14 [12554651.001]
  • [Cites] Biochem Soc Trans. 2003 Jun;31(Pt 3):723-7 [12773192.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3249-54 [12947059.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1242-55 [14570903.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):67-78 [14749127.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11898-905 [14704146.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W526-31 [15215442.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4096-100 [15217945.001]
  • [Cites] J Neurochem. 1984 Nov;43(5):1295-301 [6387047.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6485-9 [2251111.001]
  • [Cites] Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):663-8 [8224486.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [8744570.001]
  • [Cites] Gene. 1997 Oct 24;200(1-2):135-44 [9373147.001]
  • [Cites] Nat Med. 1998 Jan;4(1):50-7 [9427606.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7757-64 [9516485.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12517-22 [15699051.001]
  • [Cites] Proteins. 2005 Aug 1;60(2):232-8 [15981252.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 1;1751(1):52-9 [16054017.001]
  • [Cites] J Am Chem Soc. 2005 Oct 12;127(40):14072-9 [16201829.001]
  • [Cites] Biotechniques. 2005 Oct;39(4):575-6 [16235571.001]
  • [Cites] Nucleic Acids Res. 2006;34(17):e112 [16971460.001]
  • [Cites] J Comput Aided Mol Des. 2006 Jul-Aug;20(7-8):437-48 [17103019.001]
  • [Cites] PLoS Comput Biol. 2006 Nov 10;2(11):e153 [17096593.001]
  • [Cites] J Mol Biol. 2007 Feb 2;365(5):1446-59 [17134719.001]
  • [Cites] Folia Histochem Cytobiol. 2006;44(4):231-48 [17219717.001]
  • [Cites] Curr Opin Cell Biol. 2007 Feb;19(1):51-6 [17175152.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):222-9 [17442573.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19854-62 [17459884.001]
  • [Cites] Proteins. 2007 Dec 1;69(4):839-44 [17803236.001]
  • [Cites] Genes Cells. 2007 Dec;12(12):1329-38 [18076570.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1001-9 [18075579.001]
  • [Cites] J Comb Chem. 2008 Mar-Apr;10(2):256-66 [18271560.001]
  • [Cites] Mol Pharmacol. 2008 May;73(5):1578-86 [18314496.001]
  • [Cites] Diabetes Metab Res Rev. 2008 Oct;24(7):577-84 [18613220.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29602-12 [18753140.001]
  • [Cites] J Clin Invest. 2000 Dec;106(11):1399-407 [11104793.001]
  • (PMID = 19388049.001).
  • [ISSN] 1469-896X
  • [Journal-full-title] Protein science : a publication of the Protein Society
  • [ISO-abbreviation] Protein Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA80240; United States / NCI NIH HHS / PC / PC040758
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Neurofibromin 2; 0 / Peptides; 144131-77-1 / moesin; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2771306
  •  go-up   go-down


56. Thomas R, Duke SE, Wang HJ, Breen TE, Higgins RJ, Linder KE, Ellis P, Langford CF, Dickinson PJ, Olby NJ, Breen M: 'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. J Neurooncol; 2009 Sep;94(3):333-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, however, genomic imbalances orthologous to some of the hallmark aberrations of human intracranial tumors, including chromosome 22/NF2 deletions in meningiomas and chromosome 1p/19q deletions in oligodendrogliomas, were not major events in the dog.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):440-53 [10640979.001]
  • [Cites] Cytogenet Genome Res. 2008;122(2):110-21 [19096206.001]
  • [Cites] Vet Pathol. 2000 Mar;37(2):160-7 [10714645.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] J Small Anim Pract. 2002 Jun;43(6):240-6 [12074288.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):147-59 [12127399.001]
  • [Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1530-7 [14562028.001]
  • [Cites] Vet Pathol. 2003 Nov;40(6):659-69 [14608019.001]
  • [Cites] Vet Pathol. 2004 Jan;41(1):10-9 [14715963.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Science. 2004 May 21;304(5674):1160-4 [15155949.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] BMC Genomics. 2004 Sep 13;5:65 [15363096.001]
  • [Cites] Hereditas. 1972;71(1):163-8 [4142025.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):2090-1 [2230902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Chromosome Res. 1999;7(5):401-6 [10515215.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3636-7 [15201182.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Apr;64(4):312-22 [15835267.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2253-7 [15980208.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5654-61 [15994938.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Vet Pathol. 2005 Sep;42(5):550-8 [16145201.001]
  • [Cites] Genome Res. 2005 Dec;15(12):1831-7 [16339382.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):803-19 [16341006.001]
  • [Cites] J Vet Intern Med. 2006 May-Jun;20(3):669-75 [16734106.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):995-1006 [16897744.001]
  • [Cites] Mol Cancer. 2006;5:39 [17002787.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):327-35 [17243164.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2368-76 [17285580.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4541-4 [17510377.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1219-30 [17161458.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):245-58 [17522335.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Oct;46(10):875-94 [17620294.001]
  • [Cites] J Hered. 2007;98(5):474-84 [17702974.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1416-24 [17940511.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Lancet Neurol. 2008 Jan;7(1):14-6 [18093552.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):803-10 [17667943.001]
  • [Cites] Chromosome Res. 2008;16(1):145-54 [18293109.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]
  • [Cites] Cytogenet Genome Res. 2008;120(1-2):50-60 [18467825.001]
  • [Cites] J Vet Intern Med. 2008 May-Jun;22(3):586-95 [18466258.001]
  • [Cites] Clin Neurosurg. 2007;54:4-9 [18504889.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):293-8 [18345516.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • (PMID = 19333554.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS051190-01; United States / NINDS NIH HHS / NS / R21 NS051190; United States / NINDS NIH HHS / NS / R21 NS051190-01; United States / NINDS NIH HHS / NS / NS051190; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS183408; NLM/ PMC3225023
  •  go-up   go-down


57. McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J, Magendantz M, Jacks T: The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A; 2007 Feb 27;104(9):3261-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion.
  • We found that in the mouse embryo, expression of the Nf2 tumor suppressor, merlin, is dynamically regulated during tissue fusion: Nf2 expression is low at the leading front before fusion and high across the fused tissue bridge.
  • Mosaic Nf2 mutants exhibit a global defect in tissue fusion characterized by ectopic detachment and increased detachment-induced apoptosis (anoikis).
  • Our work reveals that regulation of Nf2 expression is a previously unrecognized means of controlling adhesion at the leading front, thereby ensuring successful tissue fusion.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • eagle-i research resources. PMID 17360635 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Dec 1;13(23):3136-48 [10601039.001]
  • [Cites] Nat Cell Biol. 2004 Jan;6(1):21-30 [14647292.001]
  • [Cites] Dev Biol. 2000 Jun 15;222(2):296-306 [10837119.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 May 7;53(17):362-5 [15129193.001]
  • [Cites] Arch Ophthalmol. 2004 Jul;122(7):1002-11 [15249365.001]
  • [Cites] Z Zellforsch Mikrosk Anat. 1971;115(2):226-64 [4102323.001]
  • [Cites] Anat Rec. 1977 Dec;189(4):625-40 [596653.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Methods Enzymol. 1993;225:361-73 [8231863.001]
  • [Cites] J Anat. 1993 Aug;183 ( Pt 1):121-9 [8270467.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):185-92 [8162073.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):664-79 [8954735.001]
  • [Cites] Curr Biol. 1997 Apr 1;7(4):281-4 [9094312.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1253-65 [9171370.001]
  • [Cites] Mol Cell Neurosci. 1998 Jul;11(4):183-93 [9675050.001]
  • [Cites] Cell. 1999 Jul 23;98(2):147-57 [10428027.001]
  • [Cites] Dev Dyn. 2005 Jun;233(2):528-39 [15844200.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12843-8 [16126904.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] Dev Biol. 2006 Jul 15;295(2):647-63 [16712836.001]
  • [Cites] Dev Dyn. 2006 Oct;235(10):2771-85 [16894610.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1225-37 [17090534.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Neurosci. 2001 Feb 1;21(3):788-97 [11157065.001]
  • [Cites] Genomics. 2002 Jan;79(1):63-76 [11827459.001]
  • [Cites] Neurology. 2002 Jun 25;58(12):1849-52 [12084890.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):354-62 [12118253.001]
  • [Cites] Dev Cell. 2002 Aug;3(2):259-70 [12194856.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):569-74 [12231351.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):752-5 [12591720.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Mar;4(3):225-36 [12612641.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Nat Rev Genet. 2003 Oct;4(10):784-93 [13679871.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Dev Biol. 2000 Apr 15;220(2):343-57 [10753521.001]
  • (PMID = 17360635.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neurofibromin 2
  • [Other-IDs] NLM/ PMC1801999
  •  go-up   go-down


58. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ: Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol; 2010 May;20(3):623-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed direct sodium bisulfite sequencing in a series of 50 meningiomas, including 27 benign meningiomas [World Health Organization (WHO) grade I], 11 atypical meningiomas (WHO grade II) and 12 anaplastic meningiomas (WHO grade III), and found hypermethylation of TIMP3 in 67% of anaplastic meningiomas, but only 22% of atypical and 17% of benign meningiomas.
  • TIMP3 is located in the chromosomal band 22q12, the allelic loss of which occurs early in meningioma tumorigenesis and preferentially targets the NF2 tumor suppressor gene.
  • Thus, TIMP3 inactivation by methylation seems fairly exclusive to meningiomas with allelic losses on 22q12 but--in contrast to NF2 mutation--appears to be involved in meningioma progression as it is associated with a more aggressive, high-grade meningioma phenotype.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Disease Progression. Down-Regulation / genetics. Humans. Male. Middle Aged

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922547.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3
  •  go-up   go-down


59. Nascimento AF, Fletcher CD: The controversial nosology of benign nerve sheath tumors: neurofilament protein staining demonstrates intratumoral axons in many sporadic schwannomas. Am J Surg Pathol; 2007 Sep;31(9):1363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This concept has recently been disputed in cases associated with neurofibromatosis type 2.
  • The amount (rare, focal, multifocal, and diffuse) and distribution (central and/or peripheral) of axons within the tumors were analyzed.
  • NFP-positive axons were identified in 11 of 20 (55%) conventional schwannomas (2 rare, 4 focal, 3 multifocal, and 2 diffuse; 5 central, 4 peripheral, and 2 central and peripheral) and in 15 of 20 (75%) cellular schwannomas (3 rare, 6 focal, and 6 multifocal; 12 central, 1 peripheral, and 2 central and peripheral).
  • Of the 20 ancient schwannomas, 7 cases (35%) showed intratumoral axons, highlighted by NFP immunostaining (1 rare, 4 focal, 1 multifocal, and 1 diffuse; 4 peripheral, 2 central, and 1 central and peripheral).
  • Most cases of gastric schwannoma showed no evidence of intratumoral axons; 9 cases (90%) were negative for NFP and only 1 case (10%) was positive (focal and central).
  • Seven of 10 cases (70%) of plexiform schwannomas were negative for NFP, whereas only 3 cases (30%) showed positive axons (2 multifocal and 1 focal; 3 central).
  • Although NFP-positive axons were most often present in the conventional and cellular variants of schwannoma, their presence was also observed in a minority of ancient, gastric and plexiform schwannomas.
  • Differentiation between neurofibroma and schwannoma in cases with overlapping cytoarchitectural features should not be based solely on the presence or absence of NFP-positive axons within a given tumor.
  • [MeSH-major] Axons / chemistry. Neurilemmoma / diagnosis. Neurofibroma / diagnosis. Neurofilament Proteins / analysis. S100 Proteins / analysis. Schwann Cells / chemistry. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Cell Differentiation. Cell Proliferation. Diagnosis, Differential. Humans. Immunohistochemistry. Neoplasm Invasiveness. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721192.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofilament Proteins; 0 / S100 Proteins
  •  go-up   go-down


60. Miyakawa T, Kamada N, Kobayashi T, Hirano K, Fujii K, Sasahara Y, Nagai Y, Shinkai H: Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom. J Dermatol; 2007 Jan;34(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
  • Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder that is caused by inactivating mutations or a loss of both alleles in the NF2 tumor-suppressor gene.
  • Bilateral vestibular schwannomas are considered to be the hallmark of this disease, with hearing loss and tinnitus which are caused by these tumors, usually presenting as the initial symptoms.
  • In addition to other tumors and ocular findings, skin abnormalities also occur in NF2, however, they are not so characteristic as neurofibromatosis type 1 (NF1).
  • We herein report a case of NF2 which occurred in a 5-year-old boy.
  • He had multiple cutaneous tumors but did not have any symptoms related to vestibular schwannomas.
  • A histopathological examination revealed these tumors to be plexiform schwannomas; we therefore suspected NF2.
  • As a result of magnetic resonance imaging with gadolinium enhancement, bilateral vestibular schwannomas were detected and a final diagnosis of NF2 was thus made.
  • The association between NF2 and multiple depigmented spots is unknown, we therefore consider that multiple cutaneous plexiform schwannomas may strongly suggest an association with NF2.
  • [MeSH-major] Neurilemmoma / pathology. Neurofibromatosis 2 / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Humans. Male. Neuroma, Acoustic / pathology


61. Kuo YH, Roos D, Brophy BP: Linear accelerator radiosurgery for treatment of vestibular schwannomas in neurofibromatosis 2. J Clin Neurosci; 2008 Jul;15(7):744-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear accelerator radiosurgery for treatment of vestibular schwannomas in neurofibromatosis 2.
  • Management of vestibular schwannomas in patients with neurofibromatosis 2 (NF2) balances growth control against preservation of hearing with the primary aim of maintaining patient quality of life.
  • Previous studies on the efficacy of stereotactic radiosurgery for vestibular schwannomas in NF2 have reported results from delivery by Gamma Knife systems.
  • Modelling studies suggest that lesional conformality is superior with Gamma Knife, but clinical studies on sporadic vestibular schwannomas show equivalent results between the two systems.
  • Our experience with LINAC radiosurgery in NF2 reported here shows good long-term growth control in four patients with vestibular schwannomas.
  • [MeSH-major] Neurofibromatosis 2 / surgery. Neuroma, Acoustic / surgery. Radiosurgery / statistics & numerical data
  • [MeSH-minor] Adult. Brain Stem / pathology. Brain Stem / physiopathology. Brain Stem / surgery. Deafness / etiology. Deafness / physiopathology. Female. Humans. Magnetic Resonance Imaging. Male. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Retrospective Studies. Treatment Outcome. Vestibular Nerve / pathology. Vestibular Nerve / physiopathology. Vestibular Nerve / radiation effects

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403208.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


62. Buccoliero AM, Castiglione F, R Degl'Innocenti D, Gheri CF, Garbini F, Taddei A, Ammannati F, Mennonna P, Taddei GL: NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. Neuropathology; 2007 Feb;27(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study.
  • One of the most common regions involved in the meningiomas tumorigenesis is chromosome 22q where the NF2 gene resides.
  • The deficiency or loss of the NF2 gene product, merlin/schwannomin, plays a role in tumor development and metastatization.
  • Several studies have indicated NF2 gene inactivation as an early tumorigenic event unrelated to the histological grade or clinical behavior.
  • On the contrary, the NF2 gene alteration rate differs between the different histotypes.
  • A pathogenesis independent from the NF2 gene has been suggested in meningothelial meningiomas.
  • In the present work, we studied the NF2 gene expression through real time-PCR (RT-PCR) in 30 meningiomas.
  • The average of the NF2 gene expression of all meningiomas was considered as reference value.
  • The average of expression of WHO grade I and II meningiomas was higher than the average of all meningiomas, whereas that of WHO grade III meningiomas was lower.
  • When we compared the NF2 gene expression in the different meningioma grades we did not note a significant difference (P = 0.698) despite the tendency to decrease from grade I to grade III.
  • The difference in NF2 gene expression between meningothelial and non-meningothelial meningiomas was statistically significant (P = 0.013).
  • Our data supports the finding that alterations in NF2 gene alteration are histotype related but not grade related.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319281.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


63. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature; 2010 Jan 21;463(7279):360-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, NF2 mutations were found in non-VHL mutated ccRCC, and several other probable cancer genes were identified.
  • These results indicate that substantial genetic heterogeneity exists in a cancer type dominated by mutations in a single gene, and that systematic screens will be key to fully determining the somatic genetic architecture of cancer.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Genes, Neurofibromatosis 2. Histone-Lysine N-Methyltransferase / genetics. Histones / metabolism. Kidney Neoplasms / genetics. Nuclear Proteins / genetics. Oxidoreductases, N-Demethylating / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2007 Apr;11(4):335-47 [17418410.001]
  • [Cites] Cell. 2007 Mar 23;128(6):1077-88 [17320160.001]
  • [Cites] Cancer Cell. 2007 May;11(5):407-20 [17482131.001]
  • [Cites] Bioinformatics. 2007 Jul 1;23(13):1689-91 [17485433.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:37-55 [17887919.001]
  • [Cites] Science. 2007 Oct 19;318(5849):447-50 [17761849.001]
  • [Cites] Oncogene. 2007 Dec 10;26(56):7792-8 [18066092.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):361-9 [18297059.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16484-9 [18948595.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1119-32 [19269025.001]
  • [Cites] Nat Genet. 2009 May;41(5):521-3 [19330029.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):459-68 [12124175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11492-7 [16061792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11486-91 [16081543.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35261-71 [16118227.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2000-11 [16488999.001]
  • [Cites] Genetics. 2006 Aug;173(4):2187-98 [16783027.001]
  • [Cites] PLoS Med. 2006 Mar;3(3):e47 [16417408.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1889-903 [17178841.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):394-404 [17450177.001]
  • [CommentIn] Future Oncol. 2010 Jun;6(6):897-900 [20528227.001]
  • (PMID = 20054297.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE17895
  • [Grant] United Kingdom / Wellcome Trust / / 077012/Z/05/Z; United Kingdom / Wellcome Trust / / 082359; United Kingdom / Wellcome Trust / / 088340; United Kingdom / Wellcome Trust / / 093867; United Kingdom / Wellcome Trust / / 077012
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin; 0 / Histones; 0 / Nuclear Proteins; EC 1.14.11.- / Histone Demethylases; EC 1.14.11.- / KDM5C protein, human; EC 1.14.11.- / UTX protein, human; EC 1.5.- / Oxidoreductases, N-Demethylating; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Set2 protein, human
  • [Other-IDs] NLM/ PMC2820242; NLM/ UKMS28099
  •  go-up   go-down


64. Hennigan RF, Foster LA, Chaiken MF, Mani T, Gomes MM, Herr AB, Ip W: Fluorescence resonance energy transfer analysis of merlin conformational changes. Mol Cell Biol; 2010 Jan;30(1):54-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 2 is an inherited autosomal disorder caused by biallelic inactivation of the NF2 tumor suppressor gene.
  • The NF2 gene encodes a 70-kDa protein, merlin, which is a member of the ezrin-radixin-moesin (ERM) family.
  • Using these tools, we find that merlin exists predominately as a monomer in a stable, closed conformation that is mediated by the central alpha-helical domain.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Structure. 2006 Apr;14(4):777-89 [16615918.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):445-9 [14990965.001]
  • [Cites] J Mol Biol. 2007 Feb 2;365(5):1446-59 [17134719.001]
  • [Cites] Trends Biochem Sci. 2007 Sep;32(9):407-14 [17764955.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C874-84 [17553936.001]
  • [Cites] Methods Cell Biol. 2008;85:381-93 [18155471.001]
  • [Cites] Biochemistry. 1998 Jan 6;37(1):33-40 [9425023.001]
  • [Cites] J Cell Biol. 1998 Feb 9;140(3):647-57 [9456324.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):403-15 [9486775.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] Biochim Biophys Acta. 1998 Sep 8;1387(1-2):1-16 [9748471.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):895-904 [10036239.001]
  • [Cites] Biotechniques. 1999 Aug;27(2):368-75 [10457846.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8447-54 [15378014.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1242-54 [15788482.001]
  • [Cites] Appl Biochem Biotechnol. 2005 Aug;126(2):149-56 [16118468.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29602-12 [18753140.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4043-51 [19351837.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34438-42 [10567424.001]
  • [Cites] Biophys J. 2000 Mar;78(3):1606-19 [10692345.001]
  • [Cites] Cell. 2000 Apr 28;101(3):259-70 [10847681.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17):4449-62 [10970839.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:113-43 [11031232.001]
  • [Cites] J Cell Biol. 2000 Nov 27;151(5):1067-80 [11086008.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7621-9 [11106646.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2723-41 [11387207.001]
  • [Cites] J Mol Biol. 2001 Jul 27;310(5):973-8 [11502006.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18559-66 [14981079.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Methods Mol Biol. 1997;63:305-24 [9113659.001]
  • [Cites] J Mol Biol. 1997 Apr 11;267(4):1039-52 [9135129.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1253-65 [9171370.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):87-90 [11753368.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2002 Mar;58(Pt 3):381-91 [11856822.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] J Cell Sci. 2002 Jun 15;115(Pt 12):2569-80 [12045227.001]
  • [Cites] J Mol Biol. 2002 May 3;318(3):901-10 [12054832.001]
  • [Cites] Mol Cells. 2002 Aug 31;14(1):108-14 [12243339.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Jan;59(Pt 1):177-9 [12499563.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):502-14 [12554651.001]
  • [Cites] Biochemistry. 2003 Oct 14;42(40):11634-41 [14529273.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):580-7 [14724586.001]
  • [Cites] J Cell Biol. 2004 Mar 1;164(5):653-9 [14993232.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • (PMID = 19884346.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078524; United States / NCI NIH HHS / CA / R01-CA78524
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / Phosphoproteins; 0 / Sodium-Hydrogen Antiporter; 0 / sodium-hydrogen exchanger regulatory factor
  • [Other-IDs] NLM/ PMC2798298
  •  go-up   go-down


65. Sakai T, Vallejo MC, Shannon KT: A parturient with neurofibromatosis type 2: anesthetic and obstetric considerations for delivery. Int J Obstet Anesth; 2005 Oct;14(4):332-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A parturient with neurofibromatosis type 2: anesthetic and obstetric considerations for delivery.
  • Neurofibromatosis type 2 is an extremely rare form of neurofibromatosis characterized by central nervous system involvement with bilateral vestibular schwannomas and spinal tumors.
  • Anesthetic management of a parturient with neurofibromatosis type 2 has not been fully reported, and the condition is challenging to obstetric anesthesiologists due to the presence of intracranial and intraspinal canal neurofibromas.
  • We present a case of neurofibromatosis type 2 referred for delivery.
  • Because of central neuraxial involvement, regional anesthesia was avoided, and the patient delivered by cesarean section under general anesthesia.
  • The importance of pre-operative diagnosis and multidisciplinary management for neurofibromatosis type 2 is emphasized and anesthetic and obstetric considerations for delivery are presented.
  • [MeSH-major] Anesthesia, General. Anesthesia, Obstetrical. Central Nervous System Neoplasms. Cesarean Section. Neurofibromatosis 2. Pregnancy Complications, Neoplastic


66. Plouin PF, Gimenez-Roqueplo AP: Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab; 2006 Sep;20(3):421-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phaeochromocytomas and paragangliomas may be sporadic or the result of several genetic diseases: multiple endocrine neoplasia type 2, neurofibromatosis 1, von Hippel-Lindau disease, succinate dehydrogenase-phaeochromocytoma-paraganglioma syndrome.
  • Familial cases are diagnosed earlier and are more frequently bilateral and recurrent than sporadic cases.
  • Patients should be followed up indefinitely, particularly if they have familial or extra-adrenal tumours.
  • [MeSH-major] Paraganglioma / complications. Paraganglioma / diagnosis. Pheochromocytoma / complications. Pheochromocytoma / diagnosis
  • [MeSH-minor] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / radiography. Adrenal Gland Neoplasms / radionuclide imaging. Aftercare. Algorithms. Diagnostic Imaging. Follow-Up Studies. Humans. Perioperative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980203.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


67. Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD: Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery; 2007 Mar;60(3):460-8; discussion 468-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.
  • OBJECTIVE: Vestibular schwannomas present significant management challenges in patients with neurofibromatosis Type 2 (NF2).
  • Facial neuropathy occurred in 8% of tumors, trigeminal neuropathy occurred in 4%, and vestibular dysfunction occurred in 4%.
  • CONCLUSION: Stereotactic radiosurgery is a safe and effective management modality for neurofibromatosis Type 2 vestibular schwannomas.
  • [MeSH-major] Hearing Loss, Sensorineural / epidemiology. Hearing Loss, Sensorineural / prevention & control. Neurilemmoma / epidemiology. Neurilemmoma / surgery. Neurofibromatosis 2 / epidemiology. Neurofibromatosis 2 / surgery. Radiosurgery / statistics & numerical data


68. Suárez C, Rodrigo JP, Ferlito A, Cabanillas R, Shaha AR, Rinaldo A: Tumours of familial origin in the head and neck. Oral Oncol; 2006 Nov;42(10):965-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumours of familial origin in the head and neck.
  • Tumours of familial origin are a rare event in the head and neck but despite this, they deserve a growing interest.
  • Familial paragangliomas are most of the time limited to the paraganglionar system, but also may be part of different syndromic associations.
  • Multiple endocrine neoplasias type 1 are characterized by the simultaneous occurrence of at least two of the three main related endocrine tumours: parathyroid, enteropancreatic and anterior pituitary.
  • Multiple endocrine neoplasia type 2 is due to a germline mutation in the RET proto-oncogene.
  • The most central clinical difference with MEN-1 is that the associated cancer can be prevented or cured by early thyroidectomy in mutation carriers.
  • Individuals with neurofibomatosis type 1 present early in life with pigmentary abnormalities, skinfold freckling and iris hamartomas, as result of NF1 gene mutation.
  • Neurofibromatosis 2 is caused by inactivating mutations of the NF2 gene, and is characterized by the development of nervous system tumours (mainly bilateral vestibular schwannomas), ocular abnormalities, and skin tumours.
  • Finally, the high rate of p16 mutations in squamous cell carcinomas and the association of p16 with familial melanoma propose p16 as an ideal candidate gene predisposing to familial squamous cell carcinomas.
  • The elucidation of the cellular processes affected by dysfunction in familial tumours of the head and neck may serve to identify potential targets for future therapeutic interventions.
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Humans. Multiple Endocrine Neoplasia / genetics. Nasopharyngeal Neoplasms / genetics. Neurofibromatoses / genetics. Paraganglioma / genetics

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857415.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 121
  •  go-up   go-down


69. Siddiqui MA, Leslie T, Scott C, Mackenzie J: Eyelid schwannoma in a male adult. Clin Exp Ophthalmol; 2005 Aug;33(4):412-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid schwannoma in a male adult.
  • Solitary lesions can occur sporadically in the general population but multiple neurofibromas are distinctive feature of neurofibromatosis type 1 and bilateral acoustic schwannomas are a feature of neurofibromatosis type 2.
  • Herein, a case of eyelid schwannoma in a 53-year-old man is described.

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033357.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


70. Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R: Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2. Clin Neurol Neurosurg; 2009 Jun;111(5):454-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2.
  • OBJECTIVE: Neurofibromatosis type 2 (NF2) is a common neurocutaneous disorder that exhibits an autosomal dominant inheritance, with a mutation at chromosome 22q12.2.
  • In general, patients present bilateral vestibular schwannomas, meningiomas and neurinomas of the central and peripheral nervous system as well as neurofibromas and gliomas.
  • There is no reported case of pulmonary meningiomas and neurinomas associated with NF2 until now.
  • PATIENT AND METHODS: Here, we present a 16-year-old girl with NF-2 associated to CNS and pulmonary tumours and we discuss the case in the backlight of the literature.
  • RESULTS: The reported patient presented a de novo NF2 germline mutation (R341X) and displayed the Wishart-type of NF-2 since she is 11 years old, with a huge anaplastic biparietal falx meningioma and a tentorium meningioma and a tumour-associated parietal mass as well as hypacusis starting at the infant age of 3 years.
  • CONCLUSION: This rare case extends our knowledge of NF2 and also raises interesting questions about the pathogenesis of meningiomas outside the CNS.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary. Neurofibromatosis 2 / complications
  • [MeSH-minor] Brain / radiography. Brain Edema. Child. Female. Genes, Neurofibromatosis 2 / physiology. Germ-Line Mutation. Humans. Lung / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed


71. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q: Merlin is a potent inhibitor of glioma growth. Cancer Res; 2008 Jul 15;68(14):5733-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis 2 (NF2) is an inherited cancer syndrome in which affected individuals develop nervous system tumors, including schwannomas, meningiomas, and ependymomas.
  • The NF2 protein merlin (or schwannomin) is a member of the Band 4.1 superfamily of proteins, which serve as linkers between transmembrane proteins and the actin cytoskeleton.
  • In addition to mutational inactivation of the NF2 gene in NF2-associated tumors, mutations and loss of merlin expression have also been reported in other types of cancers.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Int J Cancer. 2005 Dec 10;117(5):755-63 [15981204.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4463-8 [16537381.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2452-67 [16314835.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 [16894141.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8511-9 [16951163.001]
  • [Cites] Nat Genet. 2006 Oct;38(10):1142-50 [16980976.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2687-700 [17015431.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):615-24 [17083476.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):450-8 [17049657.001]
  • [Cites] Neurology. 2006 Nov 28;67(10):1863-6 [17130425.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):836-50 [16953231.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2103-19 [17210637.001]
  • [Cites] Dev Biol. 2007 Apr 1;304(1):102-15 [17258190.001]
  • [Cites] Brain Dev. 2007 Jun;29(5):273-80 [17071037.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21206-12 [17513297.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1199-207 [17891137.001]
  • [Cites] Cell Signal. 2008 May;20(5):795-802 [18160255.001]
  • [Cites] Development. 2000 Mar;127(6):1315-24 [10683183.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:113-43 [11031232.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):104-9 [11792551.001]
  • [Cites] Oncogene. 2002 Jan 31;21(6):878-89 [11840333.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Apr 1;134(1):1-5 [11996787.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] Cell. 2003 Aug 22;114(4):445-56 [12941273.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Vitam Horm. 2004;67:453-83 [15110190.001]
  • [Cites] EMBO J. 2004 Sep 15;23(18):3677-88 [15343267.001]
  • [Cites] Nat Rev Genet. 2004 Sep;5(9):691-701 [15372092.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):185-92 [8162073.001]
  • [Cites] Gene. 1995 Dec 29;167(1-2):303-6 [8566796.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):177-81 [9988268.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):182-6 [9988269.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1380-5 [15746036.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2076-86 [15688006.001]
  • [Cites] Cell. 2005 Aug 12;122(3):421-34 [16096061.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8679-89 [16204036.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):494-501 [16546963.001]
  • (PMID = 18632626.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1F32CA128335-01A1; United States / NCI NIH HHS / CA / CA135158-02; United States / NCI NIH HHS / CA / R01 CA135158-02; United States / NCI NIH HHS / CA / CA135158-01A1; United States / NCI NIH HHS / CA / F32 CA128335; United States / NCI NIH HHS / CA / R01 CA135158-01A1; United States / NCI NIH HHS / CA / R01 CA135158; United States / NCI NIH HHS / CA / R01 CA150355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / Wnt Proteins
  • [Other-IDs] NLM/ NIHMS147652; NLM/ PMC2778036
  •  go-up   go-down


72. Skarzynski H, Lorens A, Kochanek K, Mrowka M, Behr R: Bilateral auditory brainstem implantation in a patient with neurofibromatosis type II. Cochlear Implants Int; 2010 Jun;11 Suppl 1:88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral auditory brainstem implantation in a patient with neurofibromatosis type II.
  • [MeSH-major] Auditory Brain Stem Implantation / methods. Neurofibromatosis 2 / surgery. Neuroma, Acoustic / surgery. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21756589.001).
  • [ISSN] 1754-7628
  • [Journal-full-title] Cochlear implants international
  • [ISO-abbreviation] Cochlear Implants Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Cotticelli L, Romano M, Russo S, Borrelli M: Neurofibromatosis type 2: a case of ptosis. Graefes Arch Clin Exp Ophthalmol; 2007 Sep;245(9):1393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2: a case of ptosis.
  • BACKGROUND: Neurofibromatosis type 2 (NF2) is a disorder usually diagnosed later in life since the features are subtle in children.
  • The hallmark is bilateral vestibular schwannomas, which may not appear until after the second decade.
  • Here is described a rare case of NF2 associated with a superior rectus muscle paralysis and severe ptosis.
  • CASE REPORT: A 17-year-old patient with NF2 was referred to us with diagnosis of left-eye superior rectus muscle paralysis, with a later onset of unilateral severe ptosis.
  • The patient showed positive familiar history for NF (the father was affected), bilateral involvement of the acoustic nerves (schwannoma), multiple neurofibromas, and bilateral posterior subcapsular lens opacity.
  • Magnetic resonance imaging (MRI) showed bilateral acoustic neuromas in the left temporal region close to the cavernous sinus; since neurological examination and ocular motility problems had remained stationary over time, surgical correction of ptosis and strabismus was suggested.
  • CONCLUSION: Palpebral ptosis has rarely been reported in NF2.
  • [MeSH-major] Blepharoptosis / complications. Neurofibromatosis 2 / complications. Oculomotor Muscles / pathology. Ophthalmoplegia / complications

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • Genetic Alliance. consumer health - Ptosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1993 Oct;77(10):662-72 [8218038.001]
  • [Cites] Curr Opin Neurol. 2003 Feb;16(1):27-33 [12544854.001]
  • [Cites] Br J Ophthalmol. 1986 Oct;70(10):732-6 [3096370.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1996 Jul-Aug;33(4):255-9 [8827563.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Neurology. 2001 May 8;56(9):1222-4 [11342693.001]
  • [Cites] J AAPOS. 2001 Feb;5(1):9-12 [11182665.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):269-71 [16421138.001]
  • [Cites] J Invest Dermatol. 2000 May;114(5):1017-21 [10771486.001]
  • [Cites] Eye (Lond). 1997;11 ( Pt 1):12-8 [9246269.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • (PMID = 17347811.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Bouccara D, Kalamarides M, Bozorg Grayeli A, Ambert-Dahan E, Rey A, Sterkers O: [Auditory brainstem implant: indications and results]. Ann Otolaryngol Chir Cervicofac; 2007 Jul;124(3):148-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To summarize the indications and evaluate the Auditory Brainstem Implant (ABI) performances in neurofibromatosis type 2 (NF2) and other otologics indications, as postmeningitis ossified cochlea.
  • MATERIAL AND METHODS: Main and first indication of ABI is NF2.
  • Emergent indications are bilateral total ossified cochlea, vestibular schwannoma with controlateral lesions, cochlear nerve aplasia or inner ear's malformations.
  • RESULTS: In NF2 patients, best results are obtained in cases of smaller vestibular schwannoma and none, or short term, auditory deprivation.
  • CONCLUSION: These results show a clear benefit of ABI in NF2 patients, with or without previous tumor removal, in case of small tumor with a short duration of hearing loss.
  • [MeSH-minor] Brain / pathology. Calcinosis / etiology. Calcinosis / pathology. Cochlear Diseases / etiology. Cochlear Diseases / pathology. Cochlear Nerve / pathology. Cochlear Nerve / surgery. Electrodes, Implanted. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neurofibromatosis 2 / complications. Neuroma, Acoustic / complications. Neuroma, Acoustic / pathology. Neuroma, Acoustic / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320034.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Rennie AT, Side L, Kerr RS, Anslow P, Pretorius P: Intramedullary tumours in patients with neurofibromatosis type 2: MRI features associated with a favourable prognosis. Clin Radiol; 2008 Feb;63(2):193-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary tumours in patients with neurofibromatosis type 2: MRI features associated with a favourable prognosis.
  • AIM: To assess the magnetic resonance imaging (MRI) features and natural history of intramedullary tumours in patients with neurofibromatosis type 2 (NF2).
  • MATERIALS AND METHODS: Eleven NF2 patients with intramedullary spinal cord tumours were identified from the database of the multidisciplinary NF2 clinic.
  • CONCLUSION: The majority of intramedullary tumours in NF2 patients are very slow growing and share certain MRI features that differ from those of progressive or symptomatic lesions.
  • [MeSH-major] Neurofibromatosis 2 / diagnosis. Neuroma, Acoustic / diagnosis. Spinal Cord Neoplasms / diagnosis


76. Seong MW, Yeo IK, Cho SI, Park CK, Kim SK, Paek SH, Kim DG, Jung HW, Park H, Kim SY, Kim JY, Park SS: Molecular characterization of the NF2 gene in Korean patients with neurofibromatosis type 2: a report of four novel mutations. Korean J Lab Med; 2010 Apr;30(2):190-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of the NF2 gene in Korean patients with neurofibromatosis type 2: a report of four novel mutations.
  • BACKGROUND: Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome caused by the NF2 tumor suppressor gene.
  • However, the NF2 mutation characteristics in Korean patients are not sufficiently understood.
  • In this study, we conducted a comprehensive mutational analysis in 7 Korean NF2 patients by performing direct sequencing and gene-dosage assessment.
  • METHODS: We analyzed all exons and flanking regions of NF2 by direct sequencing and screened the deletions or duplications involving NF2 by multiplex ligation-dependent probe amplification.
  • RESULTS: Four novel NF2 mutations, including 2 splice-site mutations (c.364-1G>A and c.886-3C>G), 1 frameshift mutation (c.524delA), and 1 missense mutation (c.397T>C; p.Cys133Arg), were identified in our patients.
  • CONCLUSIONS: The detection rate of NF2 mutations in Korean patients (57%) is similar to those in other populations.
  • Our results provided a greater insight into the mutational spectrum of the NF2 gene in Korean subjects.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Genes, Neurofibromatosis 2. Mutation. Neurofibromatosis 2 / genetics

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445339.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / RNA Splice Sites
  •  go-up   go-down


77. Simon M, Boström JP, Hartmann C: Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery; 2007 May;60(5):787-98; discussion 787-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the NF2 gene probably account for the formation of more than half of all meningiomas.
  • On the other hand, the molecular events underlying the initiation of meningiomas without NF2 mutations have yet to be identified.

  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460514.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


78. Trotter MI, Briggs RJ: Cochlear implantation in neurofibromatosis type 2 after radiation therapy. Otol Neurotol; 2010 Feb;31(2):216-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cochlear implantation in neurofibromatosis type 2 after radiation therapy.
  • OBJECTIVE: To investigate the results of cochlear implantation in patients with neurofibromatosis Type 2 (NF2) who have previously been treated with radiation therapy to the vestibular schwannoma (VS) in their only hearing ear.
  • STUDY DESIGN: A retrospective review of the Melbourne Cochlear implant database was undertaken to identify patients with NF2 undergoing cochlear implantation in whom previous radiation therapy had been performed to control their VS (ipsilateral tumor).
  • CONCLUSION: Cochlear implantation results in improved hearing in a select group of NF2 patients who have undergone radiation treatment to control their vs.
  • [MeSH-major] Cochlear Implantation. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / radiotherapy
  • [MeSH-minor] Adult. Aged, 80 and over. Communication. Ear Neoplasms / complications. Ear Neoplasms / radiotherapy. Female. Hearing Loss / etiology. Hearing Loss / therapy. Humans. Lipreading. Magnetic Resonance Imaging. Male. Middle Aged. Neuroma, Acoustic / complications. Neuroma, Acoustic / radiotherapy. Postoperative Complications / therapy. Radiosurgery. Recovery of Function. Retrospective Studies. Speech Perception. Treatment Outcome

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887974.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Nakai Y, Zheng Y, MacCollin M, Ratner N: Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci; 2006 Mar 29;26(13):3390-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells.
  • The neurofibromatosis type 2 (NF2) gene is commonly mutated in schwannomas, Schwann cell tumors that contain cells lacking axon interaction.
  • NF2 is involved in suppression of Rac signaling, and cultured schwannoma cells contain elevated, GTP-bound, active Rac.
  • Despite these previous studies, a causal relationship between Rac activation and the abnormal cellular morphology of schwannoma is unknown.
  • We used fluorescence resonance energy transfer to follow Rac activity in normal human Schwann cells and schwannoma cells during interaction with neurons.
  • Schwannoma cells showed high Rac activity at distal regions of the cells and failed to align processes with neurites.
  • Application of a Rac-specific inhibitor, the chemical compound NSC23766, to schwannoma cells restored neuronal interaction.

  • Genetic Alliance. consumer health - Schwannoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571745.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118032; United States / NCI NIH HHS / CA / CA75824
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; EC 3.6.5.2 / rac GTP-Binding Proteins
  •  go-up   go-down


80. McClatchey AI: Neurofibromatosis. Annu Rev Pathol; 2007;2:191-216
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis.
  • As familial cancer syndromes, the neurofibromatoses exhibit complex phenotypes, comprising a range of tumor and nontumor manifestations.
  • Although the three recognized forms of neurofibromatosis (NF1, NF2, and schwannomatosis) all feature the development of nervous system tumors, their underlying genetic bases are clearly distinct.
  • Recent progress in delineating the molecular function of the NF1- and NF2-encoded proteins, together with the development and use of manipulable mouse models, has led to important advances in understanding the pathogenesis of many features of neurofibromatosis.
  • An important outcome of the study of neurofibromatosis-associated tumorigenesis has been insight into the more general molecular and cellular bases of nervous system tumors.
  • [MeSH-major] Nervous System Neoplasms / pathology. Neurilemmoma / pathology. Neurofibromatosis 1 / pathology. Neurofibromatosis 2 / pathology
  • [MeSH-minor] Animals. Disease Models, Animal. Humans. Mice. Neurofibromin 1 / genetics. Neurofibromin 1 / metabolism. Neurofibromin 2 / genetics. Neurofibromin 2 / metabolism. Peripheral Nervous System / metabolism. Peripheral Nervous System / pathology. Schwann Cells / metabolism. Schwann Cells / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039098.001).
  • [ISSN] 1553-4006
  • [Journal-full-title] Annual review of pathology
  • [ISO-abbreviation] Annu Rev Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA113733-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Neurofibromin 2
  • [Number-of-references] 148
  •  go-up   go-down


81. Laskin WB, Fetsch JF, Lasota J, Miettinen M: Benign epithelioid peripheral nerve sheath tumors of the soft tissues: clinicopathologic spectrum of 33 cases. Am J Surg Pathol; 2005 Jan;29(1):39-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign epithelioid peripheral nerve sheath tumors (BEPNSTs) have not been fully characterized, and their relationship to conventional schwannoma and neurofibroma has not been satisfactorily established.
  • Only one patient probably has neurofibromatosis type 1.
  • Immunohistochemical reactivity for Schwann cell-related markers in tumor cells included S-100 protein (20 of 20 cases), collagen type IV (10 of 10), laminin (8 of 8), nerve growth factor receptor, p75(7 of 8), CD57 (6 of 9), and glial fibrillary acidic protein (8 of 15).
  • The remaining 15 cases showed some histologic features suggestive of schwannoma, but their uniform cellularity, absence of nuclear palisading, and presence of a significant CD34-positive spindled cell population in 5 cases led to their classification as "BEPNST of indeterminate histogenesis."
  • Evaluation for loss of heterozygosity in 2 cases demonstrated deletion of genetic material on chromosome 22q and 17q involving NF2 and NF1 loci.
  • However, sequencing of NF2 coding sequences revealed no mutations.
  • Follow-up for 18 patients (median interval, 13.5 years), including 4 patients with tumors exhibiting cytologic atypia, revealed a nondestructive recurrence or persistent disease in 3 patients whose tumors lacked atypia, but no evidence of metastatic spread or tumor-related death.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613855.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neurofibromin 1; 0 / Neurofibromin 2
  •  go-up   go-down


82. Yang SM, Yu LM, Yu LM, Han DY: [Technique of hearing preservation during acoustic neuroma surgery]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Aug;43(8):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Technique of hearing preservation during acoustic neuroma surgery].
  • OBJECTIVE: To explore the possibility of hearing protection in acoustic neurinoma (AN) resection and to evaluate the effect of dynamic auditory monitoring and the effect of oto-endoscope for hearing protection.
  • Fifteen cases were solitary AN, 3 cases were diagnosed as neurofibromatosis II.
  • RESULTS: In all 18 cases, tumors were resected completely in 16 cases, but sub-totally removed in 2 cases which were II neurofibromatosis.
  • According to House-Brackmann grade system, for 18 AN patients 7 days after operation only 50.0% (9/18) were kept at grade I to II , but 88.9% (16/18) were kept at grade I to II 6 months after operation.
  • [MeSH-major] Hearing Loss / prevention & control. Neuroma, Acoustic / surgery. Otologic Surgical Procedures

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959258.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Al-Anazi AH, Al-Luwimi IM, Shawarby MA, Mertol T: Mixed vestibular schwannoma and meningioma without neurofibromatosis. Neurosciences (Riyadh); 2009 Oct;14(4):371-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed vestibular schwannoma and meningioma without neurofibromatosis.
  • The co-existence of meningioma and schwannoma as 2 distinct histologic components within the same tumor has been described in neurofibromatosis 2 (NF2), but the co-existence of both tumors without evidence of NF2 is much rarer.
  • Here, we are reporting a case of mixed schwannoma with meningioma without clinical evidence of NF2.
  • In an adult Saudi lady with progressive left-sided hearing loss, left cerebellopontine tumor was diagnosed by MRI, and the histopathological diagnosis revealed that this tumor was composed of vestibular schwannoma and meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048654.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


84. Ng YS, Lyons CJ: Oculomotor nerve palsy in childhood. Can J Ophthalmol; 2005 Oct;40(5):645-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The management of children with oculomotor nerve palsy is complicated by their variable presentation, amblyopia, potential loss of binocularity, and associated neurological disease.
  • Primary aberrant regeneration was the presenting sign in a child with neurofibromatosis type 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391633.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Massager N, Nissim O, Delbrouck C, Devriendt D, David P, Desmedt F, Wikler D, Hassid S, Brotchi J, Levivier M: Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1331-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery.
  • PURPOSE: To analyze the relationship between hearing preservation after gamma knife radiosurgery (GKR) for vestibular schwannoma (VS) and some volumetric and dosimetric parameters of the intracanalicular components of vs. METHODS AND MATERIALS: This study included 82 patients with a VS treated by GKR; all patients had no NF2 disease, a Gardner-Robertson hearing class 1-4 before treatment, a marginal dose of 12 Gy, and a radiologic and audiologic follow-up > or =1 year post-GKR.
  • [MeSH-major] Neuroma, Acoustic / surgery. Radiosurgery

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458446.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Retrosi G, Nanni L, Ricci R, Manzoni C, Pintus C: Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2. J Pediatr Surg; 2009 Jul;44(7):1458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2.
  • Schwannoma is a benign neoplasia of the peripheral nerve sheath.
  • According to the existing literature esophageal schwannoma has been reported so far only in adult patients.
  • We report the case of an 11 year old patient with neurofibromatosis, type 2, who underwent surgical excision of a plexiform schwannoma of the esophagus.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Esophagectomy / methods. Neoplasms, Multiple Primary. Neurilemmoma / diagnosis. Neurofibromatosis 2 / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


87. Jaurand MC, Fleury-Feith J: Pathogenesis of malignant pleural mesothelioma. Respirology; 2005 Jan;10(1):2-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations in the tumour suppressor genes, P16/CDKN2A and neurofibromatosis 2 (NF2), are found both in human MPM and in asbestos-exposed Nf2-deficient mice.
  • Despite a ban on asbestos use in Western countries, the incidence of MPM is increasing, due to the long delay between asbestos exposure and diagnosis.
  • [MeSH-minor] Animals. Asbestosis / complications. Cell Transformation, Neoplastic / pathology. Cocarcinogenesis. Genes, Neurofibromatosis 2. Genes, Tumor Suppressor. Humans. Mice. Polyomavirus Infections / complications. Simian virus 40. Tumor Virus Infections / complications


88. Soos S, Balasko M, Jech-Mihalffy A, Szekely M, Petervari E: Anorexic vs. metabolic effects of central leptin infusion in rats of various ages and nutritional states. J Mol Neurosci; 2010 May;41(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorexic vs. metabolic effects of central leptin infusion in rats of various ages and nutritional states.
  • In the present experiments, the anorexic (suppressing food intake and body weight) and hypermetabolic (increasing body temperature (Tc), activity, and heart rate (HR), indicating metabolic rate) responses to 7-day-long intracerebroventricular leptin infusion were compared in 2- and 6-month-old normally fed (NF2 and NF6 groups), 6-month-old high-fat-diet-induced obese (HF6), and 6-month-old calorie-restricted (CR6) rats.
  • The anorexic effects were inversely related to fat content: They were most pronounced in NF2, less in NF6, non-significant in HF6 rats, but also absent in CR6 animals of the lowest fat content.
  • In contrast, CR6 rats were hypersensitive to the metabolic effects of leptin infusion (rise in Tc and HR; biotelemetric measurements), NF2 were still sensitive, while NF6 and HF6 rats exhibited moderate or low sensitivity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 2):R1425-33 [10233036.001]
  • [Cites] Pflugers Arch. 1978 Feb 22;373(2):189-93 [565045.001]
  • [Cites] Endocrinology. 2008 Mar;149(3):1121-8 [18048492.001]
  • [Cites] FASEB J. 2004 Dec;18(15):1949-51 [15388670.001]
  • [Cites] Physiol Behav. 2002 Sep;77(1):65-77 [12213503.001]
  • [Cites] Neuropeptides. 2005 Apr;39(2):103-15 [15752544.001]
  • [Cites] J Neuroendocrinol. 2002 Nov;14(11):887-93 [12421342.001]
  • [Cites] Neuropharmacology. 2000 Jul 24;39(10):1872-9 [10884568.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Oct;56 Spec No 2:81-8 [11730241.001]
  • [Cites] Endocrinology. 1999 Sep;140(9):4015-23 [10465271.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Oct;283(4):R941-8 [12228064.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):4880-9 [15271881.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2613-20 [15044360.001]
  • [Cites] J Pharmacol Toxicol Methods. 2007 Sep-Oct;56(2):218-22 [17596971.001]
  • [Cites] Neuroendocrinology. 2005;82(5-6):256-63 [16721031.001]
  • [Cites] Diabetes. 2000 Mar;49(3):431-5 [10868965.001]
  • [Cites] Dig Dis. 2007;25(2):129-37 [17468548.001]
  • [Cites] J Clin Invest. 2000 Jun;105(12):1827-32 [10862798.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):18933-41 [16687413.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 May;24(5):639-46 [10849588.001]
  • [Cites] Diabetes. 2002 Apr;51(4):1016-21 [11916920.001]
  • (PMID = 19777381.001).
  • [ISSN] 1559-1166
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin
  •  go-up   go-down


89. O'Brien DF, Farrell M, Pidgeon CN: Combined nasal and skull base pathology: adjacent nasal schwannoma and olfactory groove meningioma. Br J Neurosurg; 2005 Oct;19(5):446-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined nasal and skull base pathology: adjacent nasal schwannoma and olfactory groove meningioma.
  • Following surgical removal of the lesion histopathology confirmed the presence of both a nasal schwannoma and an olfactory groove meningioma.
  • This dual pathology may represent a variation of neurofibromatosis type 2 (NF-2).
  • [MeSH-major] Meningioma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neurilemmoma / diagnosis. Nose Neoplasms / diagnosis. Skull Base Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455571.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Kameswaran M, Vasudevan MC, Kumar RS, Nagasundaram J, Natarajan K, Raghunandhan S: Auditory brainstem implantation: The first Indian experience. Indian J Otolaryngol Head Neck Surg; 2005 Jan;57(1):58-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multichannel auditory brainstem implants (ABI) are currently indicated for patients with neurofibromatosis type II (NF2) involving both vestibulocochlear nerves.
  • The implant is usually placed in the lateral recess of the fourth ventricle at the time of tumor resection to stimulate the cochlear nucleus.
  • We report a case of ABI done on a 15-year-old girl with bilateral vestibular schwannomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol Suppl. 2000;(27):11-4 [11211429.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):23-6 [11211432.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):3-7 [11211434.001]
  • [Cites] Otol Neurotol. 2004 Jul;25(4):485-96; discussion 496 [15241227.001]
  • [Cites] Otol Neurotol. 2003 Jan;24(1):79-82 [12544033.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 May;130(5):656-9 [15148193.001]
  • [Cites] Laryngoscope. 2004 Dec;114(12):2135-46 [15564834.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):8-10 [11211442.001]
  • (PMID = 23120129.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451539
  • [Keywords] NOTNLM ; auditory brainsterm unplants / neurofibromatosis
  •  go-up   go-down


91. Chow HY, Stepanova D, Koch J, Chernoff J: p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS One; 2010 Nov 02;5(11):e13791
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
  • BACKGROUND: NF2 is an autosomal dominant disease characterized by development of bilateral vestibular schwannomas and other benign tumors in central nervous system.
  • Loss of the NF2 gene product, Merlin, leads to aberrant Schwann cell proliferation, motility, and survival, but the mechanisms by which this tumor suppressor functions remain unclear.
  • CONCLUSIONS/SIGNIFICANCE: These results suggest that Pak functions in novel signaling pathways in NF2, and may serve as a useful therapeutic target in this disease.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):873-91 [10712203.001]
  • [Cites] J Med Genet. 2000 Dec;37(12):897-904 [11106352.001]
  • [Cites] Trends Mol Med. 2001 Apr;7(4):157-62 [11286939.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Circ Res. 2002 Apr 5;90(6):697-702 [11934838.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6023-33 [12167697.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):281-91 [12876277.001]
  • [Cites] Annu Rev Biochem. 2003;72:743-81 [12676796.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4343-54 [15331659.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4454-64 [9234703.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5139-44 [9560242.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1589-99 [9647651.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4328-39 [9687501.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):180-3 [9823899.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Mol Cell. 2005 Oct 28;20(2):237-49 [16246726.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36609-15 [16129686.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):234-42 [16415866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4463-8 [16537381.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] Cell Motil Cytoskeleton. 2007 Mar;64(3):143-56 [17183546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3261-6 [17360635.001]
  • [Cites] Biol Cell. 2008 Feb;100(2):97-108 [18199048.001]
  • [Cites] J Cell Sci. 2008 Apr 1;121(Pt 7):933-8 [18319303.001]
  • [Cites] Chem Biol. 2008 Apr;15(4):322-31 [18420139.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5236-45 [18593924.001]
  • [Cites] Oncogene. 2008 Aug 21;27(36):4900-8 [18427546.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7932-7 [18829550.001]
  • [Cites] J Am Chem Soc. 2008 Nov 26;130(47):15764-5 [18973295.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63 [19165420.001]
  • [Cites] Exp Neurol. 2009 Jul;218(1):137-44 [19409384.001]
  • [Cites] J Cell Biochem. 2009 Jul 1;107(4):579-85 [19350548.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4250-61 [19451225.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4235-49 [19451229.001]
  • [Cites] Mol Cell. 2010 Apr 23;38(2):236-49 [20417602.001]
  • (PMID = 21072183.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / R01 CA117884; United States / NCI NIH HHS / CA / CA117884
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; EC 2.7.11.1 / p21-Activated Kinases
  • [Other-IDs] NLM/ PMC2970553
  •  go-up   go-down


92. Łaniewski-Wołłk M, Gos M, Koziarski A, Szpecht-Potocka A: Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2. J Appl Genet; 2008;49(3):297-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.
  • Point mutation and loss of heterozygosity (LOH) analyses were performed in 12 Polish patients with a classic symptom of NF2 - bilateral vestibular schwannomas (BVS).
  • In 5 patients (41.7%), germline mutations were found in the NF2 gene: 2 previously reported substitutions (c.592C>T and c.52C>T) and 3 novel mutations (c.1001_1002insG, c.1029_1030insCC, c.774_778dupGAATG).
  • In addition, LOH analysis of 30 tumour samples from 10 patients revealed a molecular basis of NF2 in 3 patients (25%) that did not have any germline mutation.
  • The molecular defects in sporadic cases of NF2 are still being discussed.
  • [MeSH-major] Germ-Line Mutation / genetics. Loss of Heterozygosity. Neurofibromatosis 2 / genetics

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] J Med Genet. 2003 Feb;40(2):109-14 [12566519.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):413-9 [8012353.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 10):1901-12 [11329377.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33093-100 [11432873.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):442-4 [11684412.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):331-42 [8755919.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Am J Hum Genet. 1996 Sep;59(3):529-39 [8751853.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):384-91 [15645494.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Pathol. 2006 Mar;208(4):564-73 [16353169.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):895-904 [10036239.001]
  • [Cites] Hum Genet. 1996 Nov;98(5):534-8 [8882871.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Feb;12(2):117-27 [7535084.001]
  • [Cites] J Med Genet. 1998 Jun;35(6):450-5 [9643284.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • (PMID = 18670066.001).
  • [ISSN] 1234-1983
  • [Journal-full-title] Journal of applied genetics
  • [ISO-abbreviation] J. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


93. Nakamura E, Kaelin WG Jr: Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr Pathol; 2006;17(2):97-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors can arise in the context of hereditary cancer syndromes such as von Hippel- Lindau disease, multiple endocrine neoplasia type 2, and neurofibromatosis 1.
  • This review focuses on the genetics of these tumors and suggests a possible link between familial pheochromocytomas/paraganglioma genes and control of neuronal apoptosis during embryological development.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Fetal Development / physiology. Genetic Predisposition to Disease. Paraganglioma / genetics. Pheochromocytoma / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Sep 26;335(13):943-51 [8782503.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):2881-4 [8768845.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):491-7 [10491320.001]
  • [Cites] Mol Cancer Res. 2004 Feb;2(2):89-95 [14985465.001]
  • [Cites] Genes Dev. 1996 Jun 15;10(12):1455-66 [8666230.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Pathology. 2005 Feb;37(1):10-3 [15875728.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 1):1717-27 [7798322.001]
  • [Cites] Biochem J. 2004 Aug 1;381(Pt 3):761-7 [15104534.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48690-5 [14506252.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Dec;47(6):707-12 [9497878.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1617-27 [6796886.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] Cell Mol Neurobiol. 1994 Oct;14(5):487-505 [7621509.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26277-80 [9756852.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):247-55 [12086861.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2890-4 [11397905.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12 ):4101-4 [9398721.001]
  • [Cites] J Neurochem. 1999 Jul;73(1):429-32 [10386996.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4568-74 [11134110.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6822-5 [11156372.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5085-92 [11060309.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38 [16153592.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):574-84 [16436671.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):237-46 [12086860.001]
  • [Cites] Neuron. 2002 Jan 17;33(2):261-73 [11804573.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] Cell. 1995 Sep 8;82(5):733-42 [7671302.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1181-2 [11323050.001]
  • [Cites] JAMA. 1996 Nov 20;276(19):1575-9 [8918855.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]
  • [Cites] Neuron. 2002 Jan 17;33(2):156-8 [11804563.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E83 [14691554.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2063-8 [7608256.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] Hum Mol Genet. 2001 May 1;10 (10 ):1019-27 [11331612.001]
  • [Cites] Neuron. 1995 May;14(5):927-39 [7748560.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4082-90 [12912907.001]
  • [Cites] J Med Genet. 2002 Sep;39(9):617-22 [12205103.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27509-12 [9346879.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):190-5 [12673678.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] J Cell Biochem. 2004 Jun 1;92 (3):491-501 [15156561.001]
  • [Cites] Medicine (Baltimore). 1991 Jan;70(1):46-66 [1988766.001]
  • [Cites] Hum Mol Genet. 2001 May 1;10 (10 ):1029-38 [11331613.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):728-33 [14974914.001]
  • [Cites] J Neurochem. 2003 Apr;85(2):318-28 [12675908.001]
  • [Cites] J Med Genet. 1995 Dec;32(12):934-7 [8825918.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • (PMID = 17159241.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9061-61-4 / Nerve Growth Factor; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Number-of-references] 63
  •  go-up   go-down


94. Baser ME, Rai H, Wallace AJ, Evans DG: Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation. Fam Cancer; 2005;4(4):321-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
  • Neurofibromatosis 2 (NF2) is caused by inactivating mutations of the NF2 tumor suppressor gene.
  • Somatic NF2 mutations also occur in a high proportion of human primary malignant mesotheliomas.
  • We report an elderly man with NF2, malignant mesothelioma, and a constitutional NF2 missense mutation.
  • The long latent period for mesothelioma in this patient (61 years) raises the possibility that the type of mutant NF2 allele could affect mesothelioma tumorigenesis or progression.
  • [MeSH-major] Genes, Neurofibromatosis 2. Mesothelioma / complications. Mesothelioma / genetics. Neurofibromatosis 2 / genetics. Occupational Exposure / adverse effects. Pleural Neoplasms / genetics
  • [MeSH-minor] Aged. Asbestos / adverse effects. Humans. Male. Mutation, Missense. Neuroma, Acoustic / etiology. Polymerase Chain Reaction


95. Stamenkovic I, Yu Q: Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci; 2010 Sep;11(6):471-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations of neurofibromatosis type 2 (NF2) gene lead to the development of schwannomas, meningiomas, and ependymomas.
  • Mutations of NF2 gene were also found in thyroid cancer, mesothelioma, and melanoma, suggesting that it functions as a tumor suppressor in a wide spectrum of cells.
  • The product of NF2 gene is merlin (moesin-ezrin-radixin-like protein), a member of the Band 4.1 superfamily proteins.
  • Accumulating data also suggested an emerging role of merlin as a negative regulator of growth and progression of several non-NF2 associated cancer types.